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Abstract: 
Contingent upon concentration, reactive oxygen species (ROS) influence cancer evolution in 
apparently contradictory ways, either initiating/stimulating tumorigenesis and supporting 
transformation/proliferation of cancer cells or causing cell death. To accommodate high ROS levels, 
tumor cells modify sulfur-based metabolism, NADPH generation and the activity of antioxidant 
transcription factors. During initiation, genetic changes enable cell survival under high ROS levels 
by activating antioxidant transcription factors or increasing NADPH via the pentose phosphate 
pathway (PPP). During progression and metastasis, tumor cells adapt to oxidative stress by 
increasing NADPH in various ways, including activation of AMPK, the PPP, and reductive glutamine 
and folate metabolism. 
1. Introduction
Oxidative stress, defined as a relative excess of reactive oxygen species (ROS) when compared 
with antioxidants, has been linked to neurodegenerative disease, cardiovascular disease, diabetes 
mellitus and many other pathologies (Sies, 2015). These associations emphasise that a balance 
must be struck between the relative abundance of ROS and antioxidants. Cells possess complex 
biochemical and genetic mechanisms to maintain such a balance, and it is clear that their 
perturbation can have profound pathophysiological consequences. 
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Cancer cells exhibit aberrant redox homeostasis, but whilst ROS are pro-tumorigenic, high ROS 
levels are cytotoxic (Reczek et al., 2017). Specifically, hyperproliferation of tumor cells is 
accompanied by high ROS production, but they are adapted to thrive under conditions where this 
oxidative burden pushes redox balance away from a reduced state; tumor cells achieve this by 
increasing their antioxidant status to optimise ROS-driven proliferation, whilst at the same time 
avoiding ROS thresholds that would trigger senescence, apoptosis or ferroptosis (Dodson et al., 
2019; Redza-Dutordoir and Averill-Bates, 2016). Since realignment of redox underpins how tumor 
cells tolerate high ROS levels, emphasis has been placed in this review on the biochemistry of 
reduced glutathione (GSH, L-γ-glutamyl-L-cysteinyl-glycine), thioredoxins (TXN1 and TXN2) and 
NADPH, and the mechanisms that govern their abundance under normal physiological conditions 
and during the initiation, progression and metastatic stages of cancer, as well as post-therapy 
recurrence. We also discuss heterogeneity inherent in the late stages of the evolution of cancer that 
may explain the apparently anomalous effects of antioxidants on the development and metastatic 
spread of different types of malignant disease. 
 
2. Time-dependent cellular adaptations to oxidative stress in normal cells 
Cells generate ROS and reactive nitrogen species (RNS) as an unavoidable consequence of 
metabolism, and whilst they are potentially harmful, these species are used as intracellular signaling 
molecules (see Box 1) (Halliwell and Gutteridge, 2015). To ensure ROS/RNS signaling processes 
are maintained and oxidative damage avoided, cells possess an array of antioxidant systems (Box 
2). Besides those direct-acting antioxidants, cells are also equipped with indirect-acting antioxidant 
systems that either limit the formation of ROS/RNS or detoxify the reactive metabolites they generate 
(Box 3). A disproportionate increase in ROS/RNS relative to antioxidant capacity, is referred to as 
oxidative stress, and this is countered by the cell in various ways. In this context, GSH and TXN 
(Box 4) play central roles in countering oxidative stress, but their ability to do so is underpinned by 
NADPH which maintains both in a reduced state (Box 5). 
Cells adapt to oxidative stress in the short-term by metabolic reprograming and in the longer 
term by genetic reprograming. Upon acute exposure to ROS, NADPH production by G6PD plays a 
pivotal role in mitigating oxidative stress. Upon experiencing non-toxic threshold levels of H2O2, cells 
activate G6PD and reroute glucose metabolism from glycolysis through the oxidative arm of the PPP 
towards nucleotide synthesis, thereby allowing increased reduction of NADP+ to NADPH (Kuehne et 
al., 2015). This rapid metabolic rerouting is due to alleviation of the negative feedback regulation of 
G6PD activity exerted by NADPH, which occurs constitutively under non-stressed conditions, and is 
a consequence of acute depletion of NADPH caused by ROS (Dick and Ralser, 2015). In turn, the 
increase in NADPH enables GSR1 and TXNRD1/2 to augment the GSH- and TXN1/2-based 
antioxidant systems, subduing ROS to homeostatic levels. 
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      When exposed to non-toxic doses of H2O2 for modest periods (e.g. 15 min), cells employ redox 
switches (see Box 6) in glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and pyruvate kinase 
M2 (PKM2) to block glycolysis and increase glucose catabolism via the PPP, causing accumulation 
of upper glycolysis intermediates, a spill-over of glucose-6-phosphate into the oxidative arm of the 
PPP, and increased production of NADPH by G6PD to ameliorate oxidative stress (Figure 1): the 
redox switch in GAPDH involves Cys-152, and in PKM2 involves Cys-358. Under these conditions, 
GAPDH activity can be further increased by phosphorylation by ataxia-telangiectasia mutated 
(ATM), as a consequence of formation of an intermolecular disulfide bridge in ATM at Cys-2991, 
which also increases flux through the PPP (Cosentino et al., 2011). The effects of ROS on GAPDH, 
PKM2 and G6PD activities are likely co-ordinated with oxidation of Cys residues in at least six protein 
subunits within complexes I, III and IV of the mitochondrial electron transport chain that contain Fe-
S clusters, resulting in decreased O2 consumption and a decrease in ROS production (van der Reest 
et al., 2018). Acute oxidative stress may also inhibit phosphatase and tensin homologue (PTEN), by 
oxidising Cys-124, and in so doing activate PKB/Akt by PI3K, upregulating antioxidant gene 
expression and increasing cell survival (Sakamoto et al., 2009; van der Reest et al., 2018). 
      A NO−based protective mechanism against acute oxidative stress has been reported that 
entails increased flux through the PPP resulting from S-nitrosylation of PKM2 (Zhou et al., 2019). In 
this case, NOS3 activity increases in proximal tubule endothelial cells upon acute kidney injury, 
causing accumulation of S-nitroso coenzyme A (SNO-CoA) and S-nitrosylation of PKM2 at Cys-423 
and Cys-424, which results in inhibition of the kinase, diversion of glucose metabolism through the 
PPP, increased NADPH production and diminished ROS.  
      In contrast to acute oxidative stress, which can largely be resolved by metabolic rerouting, 
adaptation to chronic oxidative stress involves activation of genetic programs. In the short-to-medium 
time-span, oxidative stress can alter the abundance and/or subcellular distribution of hypoxia-
inducible factor-1α (HIF-1α) that leads to metabolic reprogramming. Traditionally this involves 
hypoxia and oxidation of Cys-326 in PHD2 that stabilises HIF-1α and results in transcriptional 
changes that lead to a switch from glucose oxidation to glycolysis (Lee et al., 2016). Importantly, in 
chronic oxidative stress models that involve accumulation of endogenous electrophiles or depletion 
of GSH/TXN, adaptation entails upregulation of antioxidant genes (Blackburn et al., 2006; Chen et 
al., 2016; Patterson et al., 2013; Zheng et al., 2015). 
 
3. Molecular basis for adaptation to oxidative stress 
3a) Transcription factors that control intracellular redox 
It is established that many transcription factors, including activator protein-1 (AP-1), HIF-1α, heat 
shock factor 1 (HSF1), nuclear factor-κB (NF-κB), nuclear factor-erythroid 2 p45-related factor 2 
(NRF2), and tumor protein p53 (TP53, or Trp53 in mice), are activated by ROS and regulate the 
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redox status of cells (reviewed in (Marinho et al., 2014)). Whilst these transcription factors have all 
been implicated in carcinogenesis, the activities of forkhead box, class O (FOXO) and peroxisome 
proliferator-activated receptor-gamma coactivator-1α (PGC-1α), also increased by ROS (Brown and 
Webb, 2018; Guo et al., 2018), contribute to redox status and are implicated in carcinogenesis. 
Moreover, BTB and CNC homology 1 (BACH1), a repressor of the oxidative stress response that 
antagonises NRF2 (Tan et al., 2013), is itself inhibited by pro-oxidants and also influences cancer 
evolution, including metastasis (Zhang et al., 2018a).  
 
3b) Stratified responses of antioxidant transcription factors 
The extent to which individual members of the above network of antioxidant transcriptions are 
differentially activated by oxidative stress is uncertain, though it is improbable that all are activated 
simultaneously. Rather, different transcription factors likely respond to distinct threshold levels of 
ROS/RNS, in a concentration- and/or time-dependent manner that is probably attuned to the 
coexistence of metabolic stress, proteotoxic stress, hypoxia, inflammation or DNA damage. Because 
it regulates a wide spectrum of antioxidant and detoxification genes, NRF2 provides a principal 
inducible defence against oxidative stress (Hayes and Dinkova-Kostova, 2014; Sies et al., 2017), 
but whether it is more readily activated by ROS than other redox-responsive transcription factors is 
unclear. Nevertheless, assuming NRF2-directed gene expression provides an initial means to adapt 
to oxidative stress, it may offer a type of ‘floodgate’ protection, analogous to that proposed for PRDXs 
(see Box 7), in which only once the antioxidant genes induced by NRF2 upon oxidative stress are 
overwhelmed at a particular ROS threshold are the other antioxidant transcription factors within the 
network activated (Figure 2). A modification of the ‘floodgate’ model would include induction by 
NRF2 of Krüpple-like factor 9 (KLF9), which is a DNA-binding, transcriptional regulator that 
downregulates the antioxidant genes TXNRD2 and PRDX6 (Chhunchha et al., 2019; Zucker et al., 
2014), and induction of KLF9 would shut-down antioxidant defences when ROS levels exceed a 
certain threshold or duration. In this scenario, other members of the network would only be activated 
when the antioxidant capacity of NRF2-target genes is exceeded - or when KLF9 is induced. Once 
NRF2-directed floodgate defences have been breached, the question of whether individual 
antioxidant transcription factors are activated in a stratified or coordinated manner is uncertain. 
A ‘hierarchical’ or ‘rheostat’ response to oxidative stress has been proposed that places NRF2 
as a first-tier defence (activated by modest increases of ROS/RNS), with AP-1 and NF-κB as a 
second-tier defence (activated by higher ROS/RNS levels), and a third and final tier involving 
activation of apoptosis (Xiao et al., 2003). Within this model, it is plausible that FOXO, PGC-1α and 
HIF-1α are activated by higher levels of ROS/RNS than are required to activate NRF2, and lower 
levels of ROS/RNS than required to stimulate apoptosis, but where they feature relative to AP-1 and 
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NF-κB is a matter of conjecture. It can also be argued that TP53, which controls cell cycle arrest, 
senescence and apoptosis, provides a ‘final’ response to excessive ROS levels. 
Little has been reported about cross-talk between antioxidant transcription factors. Cross-talk 
between NRF2 and TP53 has been revealed using a bacterial artificial chromosome−GFP platform 
with quantitative high-throughput confocal microscopy to examine responses to oxidative stress 
caused by diethylmaleate and DNA damage caused by etoposide (Hiemstra et al., 2017). This is an 
approach that should be extended to define thresholds for various stressors that activate members 
of the antioxidant transcription factor network and tipping points for adaptation to stress. In this 
context, it should be noted that NRF2 regulates the expression of HSF1 (Paul et al., 2018) and 
overexpression of the NF-κB p65/RelA subunit antagonises NRF2 by depriving it of CBP and 
recruiting histone deacetylase 3 (Liu et al., 2008) and that when oxidative stress is sufficient to cause 
DNA damage, the ensuing activation of TP53 results in antagonism of NRF2, thereby heightening 
oxidative stress and facilitating apoptosis (Faraonio et al., 2006); together, these findings suggest 
NRF2 is downregulated by oxidative stress sufficient to cause inflammation and pro-apoptotic 
signaling. It has also been reported that FOXO transcription factors can interact with PGC-1α and 
TP53 in a stimulus-dependent fashion (Eijkelenboom and Burgering, 2013). 
 
3c) The antioxidant transcription factor network 
Members of this network each controls a distinct spectrum of antioxidant genes (Table 1), and each 
is implicated in tumorigenesis in different ways. 
NRF2 is the principal regulator of intracellular redox homeostasis and transactivates genes as a 
heterodimer with a small musculoaponeurotic fibrosarcoma (MAF) protein. As shown in Table 1, 
NRF2 transactivates a wide spectrum of antioxidant genes upon exposure to ROS or soft 
electrophiles (Hayes and Dinkova-Kostova, 2014; Hayes JD; Yamamoto et al., 2018). An interesting 
feature of NRF2 is that it does not regulate SOD1 or SOD2, and so its activation will not directly 
quench O2–-based redox signaling. It is not clear whether NRF2 can repress pro-oxidant genes, but 
it has been reported to downregulate NOX4 and, through its ability to repress the expression of 
genes encoding interleukin-1β (IL-1β) and IL-6, along with induction of the gene encoding 
peroxisome proliferator-activated receptor gamma (PPARγ), NRF2 dampens the levels of ROS 
formed during inflammation (Kobayashi et al., 2016). NRF2 mediates the protective effects of many 
cancer chemopreventive agents but it is also thought to support the latter stages of tumorigenesis 
(Rojo de la Vega et al., 2018). Its upregulation in cancer cells can increase serine biosynthesis 
through its ability to positively control ATF4-mediated induction of phosphoglycerate dehydrogenase, 
phosphohydroxythreonine aminotransferase, phosphoserine phosphatase and SHMT2 that support 
GSH and nucleotide synthesis (DeNicola et al., 2015), though it should be recognised that ATF4 is 
activated by the integrated stress response that will likely be upregulated during tumorigenesis. 
 6 
Based on a computational method that analyses patterns of mutational signatures in cancer, 
Stephen Elledge and colleagues have classed the gene encoding NRF2 (i.e. NFE2L2) as an 
oncogene, and that encoding its principal repressor Kelch-like ECH-associated protein 1 (i.e. 
KEAP1) as a tumor suppressor (Davoli et al., 2013). 
BACH1 binds DNA as a heterodimer with small MAF proteins, and is best known for its ability to 
repress HMOX1, and to a substantially lesser extent other antioxidant genes (MacLeod et al., 2009; 
Nishizawa et al., 2020). Upon binding heme and exposure to pro-oxidant agents, BACH1 is 
degraded, enabling NRF2 to transactivate genes it represses. Besides repression of antioxidant 
genes, BACH1 contributes positively to the expression of genes for metalloproteinase-1 (MMP-1) 
and CXCR4, and therefore supports metastatic disease (Liang et al., 2012). Moreover, BACH1 
directs metabolic reprogramming by increasing expression of hexokinase 2 and Gapdh (Wiel et al., 
2019) and suppresses expression of mitochondrial electron transport chain genes (Lee et al., 2019) 
increasing glycolysis and supressing mitochondrial TCA metabolism, each hallmarks of cancer. 
AP-1 represents a family of dimeric transcription factors comprising combinations of Jun (c-Jun, 
JunB, JunD), Fos (c-Fos, FosB, Fra-1, Fra-2), ATF (ATFa, ATF2, ATF3, ATF4), JDP (JDP-1, JDP-
2) and MAF (c-MAF, MAFA, MAFB, MAFF, MAFG, MAFK) (Bejjani et al., 2019). Table 1 shows they 
exert antioxidant effects through induction of genes that scavenge ROS, synthesise GSH, suppress 
levels of free iron and metabolise pro-oxidant xenobiotics (Glorieux et al., 2016; Soriano et al., 2009). 
AP-1 members include oncogenes that can transform cells and are involved in cell proliferation, 
whilst others inhibit tumorigenesis, suggesting their effects are context dependent (Eferl and 
Wagner, 2003; Shaulian and Karin, 2001). 
FOXO forkhead motif-containing FOXO1, FOXO3, FOXO4 and FOXO6 support cellular homeostasis 
in various ways (Eijkelenboom and Burgering, 2013). They augment antioxidant status by inducing 
genes that eliminate ROS and improve mitochondrial redox and suppress levels of free transition 
metal ions by increasing levels of metallothionein and ceruloplasmin (Klotz et al., 2015). Besides 
responding to ROS, FOXOs also respond to nutrients and regulate genes involved in cell cycle arrest 
such as GADD45 and apoptosis (Eijkelenboom and Burgering, 2013). In cancer cells, FOXO can 
induce genes for MMP-9 and MMP-13 and may therefore aid epithelial-to-mesenchymal transition 
(EMT) required for metastatic spread (Liou and Storz, 2010). 
PGC-1α transcriptional coactivator is a master regulator of mitochondrial biogenesis. It increases 
oxidative phosphorylation by activating PPARγ and nuclear respiratory factors 1 and 2, also 
increases antioxidant capacity (Table 1) as well as decreasing mitochondrial production of ROS by 
activating uncoupling protein-1 and -2, and stimulating mitochondrial biogenesis (Guo et al., 2018; 
Kaarniranta et al., 2018; St-Pierre et al., 2006; Valle et al., 2005). In cancer, activation of PGC-1α 
can exert both positive and negative effects in that it supports survival and metabolic flexibility of 
tumor cells whilst also exhibiting anti-metastatic effects through inhibition of EMT (Gravel, 2018). 
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HIF-1α regulates expression of GSH-based antioxidant genes under hypoxic conditions (Lu et al., 
2015; Stegen et al., 2016). It also exerts antioxidant effects by inducing genes for lactate 
dehydrogenase and pyruvate dehydrogenase kinase 1, the latter of which inhibits pyruvate 
dehydrogenase; together, these enzymes direct glucose catabolism from the TCA cycle to lactate, 
thereby decreasing mitochondrial ROS production (Samanta and Semenza, 2017). Activation of HIF-
1α increases expression of proangiogenic genes such as that for vascular endothelial growth factor 
(VGEF), which is associated with metastatic disease (Semenza, 2012). 
HSF1 responds to stressors that cause protein misfolding by inducing genes encoding heat shock 
protein chaperones. However, it also responds to ROS through Cys-35 and Cys-105 (Ahn and 
Thiele, 2003), and induces antioxidant genes (Table 1) (Kovacs et al., 2019). HSF1 upregulation 
commonly occurs as a means of protecting tumor cells against diverse stresses (Dong et al., 2019).  
NF-κB represents a family of transcription factors that comprise heterodimer or homodimer 
combinations of p50, p52, p65/RelA, RelB and c-Rel subunits, which provide an inducible first-line 
defence against infection and other damaging agents (Perkins, 2007). Although NF-κB orchestrates 
an adaptive response to eradicate invading pathogens, by inducing expression of cytokines, 
chemokines and receptors, and to repair tissue damage, it also regulates expression of antioxidant 
genes (Morgan and Liu, 2011). However, as NF-κB regulates expression of the prooxidant genes 
CYP2E1, NOX2, XOR, NOS2, COX2, ALOX5 and ALOX12 ((Morgan and Liu, 2011); 
http://www.bu.edu/nf-kb/gene-resourses/target-genes/) it may contribute little to adaptation to 
oxidative stress. Constitutive activation of NF-κB is observed in many cancers, where it promotes 
the survival, proliferation and metastasis of tumor cells by increasing expression of anti-apoptotic 
genes, cyclins, MMPs, cell adhesion genes and pro-angiogenic genes (Perkins, 2012). It also 
favours a metabolic switch to glycolysis and controls the tumor microenvironment by directing the 
pro-tumorigenic actions of immune cells (Taniguchi and Karin, 2018). 
TP53 increases antioxidant status by transactivating genes encoding enzymes/proteins that 
scavenge ROS, support GSH synthesis, increase NADPH production, detoxify xenobiotics and 
trans-repress genes for the pro-oxidant enzymes NOS2 and COX2 (Maillet and Pervaiz, 2012; 
Nguyen et al., 2018). The increase in production of NADPH affected by TP53 arises through 
upregulation of TP53-induced glycolysis and apoptosis regulator (TIGAR), which acts as a fructose-
2,6-bisphosphatase and thereby decreases glycolysis and increases flux through the oxidative arm 
of the PPP (Cheung et al., 2013). Conversely, TP53 also exerts pro-oxidant effects by upregulating 
TP53-inducibe genes (PIGs) including PIG3, which is a quinone oxidoreductase/ξ-crystallin 
producing ROS by redox cycling quinones and p67phox that activates the NOX2 complex (Italiano 
et al., 2012; Porte et al., 2009). TP53 protects against tumorigenesis primarily by controlling 
expression of genes involved in cell cycle arrest, senescence and apoptosis (Bieging et al., 2014). 
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4. Life and death of cells is heavily influenced by their redox status 
4a) Contributions of redox to physiology and cell signaling 
Typically, ROS signaling involves O2– production by NOX or mitochondria, which following reduction 
to H2O2 provides an effector molecule (Ushio-Fukai, 2009). Classic examples of ROS-mediated 
regulation include insulin/growth factor signaling (Tiganis, 2011) and transient receptor potential 
(TRP) channel-mediated cation signaling (Andersson et al., 2008). In addition, RAS proteins contain 
reactive Cys residues that are susceptible to modifications by ROS/RNS that alter their signaling 
activities (Messina et al., 2019). In the case of insulin/growth factor signaling, ligand binding to the 
cognate receptor(s) stimulates production of O2– by NOX enzymes that are closely juxta-positioned, 
with a resultant transient increase in H2O2 causing reversible inactivation of protein tyrosine 
phosphatases (e.g., PTP1B, PTPN2 and PTPN11) and the lipid phosphatase PTEN. Inactivation of 
these enzymes allows short-term de-repression of insulin/growth factor signalling and increased 
activity of various downstream mitogen-activated protein kinase (MAPK) enzymes, which leads to 
cell proliferation. Such inactivation of protein and lipid phosphatases occurs because H2O2 oxidises 
their active-site cysteines to sulfenic, sulfinic or S-glutathionylated forms (see Box 6), thereby 
inhibiting their activities until the oxidised active-site Cys is cycled back to its reduced form by the 
actions of TXN, TXNRD, SRXN, GRX and NADPH (Figure 3). The duration and magnitude of the 
NOX-derived H2O2 redox signal is controlled by PRXN enzymes, which are themselves recruited to 
growth factor receptors and associated NOX shortly after receptor stimulation. Because the activity 
of PRXN can be suppressed by phosphorylation, and reactivated by phosphatases, they allow tight 
spatiotemporal control of redox signaling around growth factor receptors (Rhee et al., 2012). 
For TRP channels, ROS and RNS activate TRPA1, TRPM2, TRPM7, TRPML1 and TRPML2, 
causing stimulation of Ca2+ signaling resulting in diverse responses including chemosensitisation/ 
pain, inflammation, proliferation, cytoprotection and cell death (Zhang et al., 2018b). TRPA1 is best 
understood in terms of its response to H2O2, 4-HNE and 15d-PGJ2 (Andersson et al., 2008). Within 
human TRPA1, Cys-414, Cys-421, Cys-621, Cys-641 and Cys-665 contribute to regulation of the 
channel by electrophiles (Hinman et al., 2006; Macpherson et al., 2007). Cryo-electron microscopy 
has confirmed that Cys-621, Cys-641 and Cys-665 are highly reactive (Paulsen et al., 2015), but 
further experiments are required to determine how TRP channels are activated by ROS/RNS. 
 
4b) Oxidative stress activates cell death pathways 
ROS are potent stimulators of apoptosis and can activate the intrinsic mitochondrial pathway, the 
extrinsic death receptor pathway and the ER stress pathway (Redza-Dutordoir and Averill-Bates, 
2016). In each of these instances, mitochondria are central to triggering apoptosis. ROS stimulate 
events that lead to loss of the inner mitochondrial membrane permeability and control of the 
mitochondrial permeability transition pore complex, disrupting membrane potential and resulting in 
release of cytochrome c and activation of caspases -3, -6 and -7 (Orrenius et al., 2015). 
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Whilst under conditions of mild oxidative stress TP53 contributes to adaptation by inducing 
antioxidant genes, under more stringent conditions TP53 orchestrates apoptosis by stimulating 
production of ROS. TP53-target genes that stimulate apoptosis include PIG3 and PIG6, 
mitochondrial proline dehydrogenases that produce ROS indirectly by providing carbon for other 
mitochondrial dehydrogenases (Goncalves et al., 2014; Porte et al., 2009). Activation of TP53 by 
high levels of ROS induces genes for BAX, PUMA and p66Shc which perturb mitochondrial function 
and cause release of cytochrome c and increased ROS production (Liu and Xu, 2011). Also, when 
TP53 is activated under proapoptotic conditions, it represses the expression of SOD2 and several 
NRF2-target genes (Faraonio et al., 2006). 
ROS can also trigger ferroptosis, an iron-dependent form of cell death, distinct from apoptosis, 
autophagy and necrosis (Dixon et al., 2012), requiring redox-cycling of Fe2+/Fe3+ that stimulates 
peroxidation of membrane phospholipids (Yang et al., 2014). Free intracellular redox-active iron 
allows increased ROS production via Fenton chemistry and/or increased lipoxygenase activity 
(Stockwell et al., 2017; Yang et al., 2016b). In turn, this results in oxidation of membrane 
phospholipid-PUFAs, presumably altering membrane pores, integrity or curvature (Dixon and 
Stockwell, 2019). Evidence indicates that GPX4 and maintenance of intracellular cysteine levels are 
each important in suppressing ferroptosis as the GPX4 inhibitor RSL-3, and the cystine/glutamate 
antiporter xCT inhibitor erastin, can markedly stimulate death in cancer cells harbouring oncogenic 
RAS (Yang and Stockwell, 2008). Also, activation of the tumor suppressor p14ARF by ROS can 
stimulate ferroptosis by activating TP53 and suppressing the activity of NRF2, thereby 
downregulating SLC7A11 and diminishing xCT activity (Chen et al., 2017). 
It is becoming increasingly apparent that redox signaling strongly influences apoptosis, and 
ferroptosis (Benhar, 2020). Thus, the activities of the Fas receptor, BAX, cIAP, XIAP, caspase-9 and 
caspase-3 can be modified by S-nitrosylation, S-glutathionylation, S-persulfidation or thiol oxidation. 
Ferroptosis is antagonised by ferroptosis suppressor protein 1 (FSP1) in a reaction in which ubiquinol 
(CoQH2) traps lipid peroxyl radicals and generates ubiquinone (CoQ), and FSP1 regenerates CoQH2 
using NADPH. Future studies are required to determine the extent to which redox switches controlled 
by the GSH and/or TXN antioxidant systems suppress apoptosis and/or ferroptosis and the triggering 
of regulated cell death. 
 
5. Oxidative stress increases cancer risk 
It is recognised that chronic inflammation, with cross-talk between myeloid cell-derived ROS and 
TNFα-mediated signaling, can lead to carcinogenesis (Canli et al., 2017). It is equally well known 
that sustained exposure to high ROS levels can damage DNA, and that a COSMIC mutation 
signature exists which is associated with oxidative DNA damage (Rose Li et al., 2020). The clearest 
evidence that ROS may increase the risk of cancer, when antioxidant defences are insufficient to 
provide protection against oxidative stress, comes from knockout of O2–-scavenging enzymes. 
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Thus, mice homozygous nulled for cytoplasmic Sod1, or heterozygous nulled for mitochondrial Sod2, 
exhibit evidence of severe oxidative damage and develop cancer spontaneously (Gill et al., 2016). 
In the case of H2O2-scavenging enzymes, loss of certain genes encoding Prdx and selenium-
dependent Gpx enzymes predispose to tumorigenesis. Specifically, Prdx1-/- and Prdx1+/- mice exhibit 
increased oxidative DNA damage, and the aging mutant mice exhibit a higher spontaneous 
incidence of hepatocellular carcinoma, fibrosarcoma, osteosarcoma, islet cell adenoma, lung 
adenocarcinoma and breast adenocarcinoma than age-matched Prdx1+/+ mice (Neumann et al., 
2003); by contrast, Prdx2-/-, Prdx4-/- and Prdx6-/- mice do not spontaneously develop cancer 
(Hampton et al., 2018). Gpx1-/- and Gpx2-/- mice are healthy under normal laboratory conditions but 
Gpx1/2 double knockout mice are susceptible to ileocolitis upon weaning and develop ileal and 
colonic tumors at 6 months of age that are dependent on the presence of commensal microflora 
(Chu et al., 2004). Interestingly, Cat-/- mice show differential sensitivity to oxidants and peroxisomal 
function but do not suffer increased risk of cancer (Hwang et al., 2012). 
Heightened production of HO increases susceptibility to tumorigenesis by modifying DNA 
(Halliwell and Gutteridge, 2015). Consistent with this notion, patients with iron overload or 
haemochromatosis have a greater cancer risk (Torti et al., 2018). However, whilst ferritin-deficient 
mice have been reported, it is not known if iron-replete ferritin-knockout mice are more susceptible 
to cancer. In chronic inflammation, levels of ONOO– may increase substantially, which following 
combination with CO2 leads to formation of nitrosoperoxycarbonate that decomposes to CO3– and 
NO2, and which in turn initiate selective oxidation and nitration of guanine in DNA, leading to 
guanine−thymidine cross-links (Shafirovich and Geacintov, 2017). 
As increases in steady-state levels of ROS are associated with heightened risk of tumorigenesis, 
it could be extrapolated that chronic loss of antioxidant status is associated with a similar risk. 
Evaluating a role for GSH in modulating the risk of carcinogenesis is confounded by the fact that 
knockout of Gclc or Gss is embryonically lethal. By contrast, knockout of Gclm has a less profound 
effect on GSH, with levels in liver, kidney, pancreas and erythrocytes of mutant mice being ∼15% of 
that in wild-type (Yang et al., 2002). Whilst fibroblasts prepared from Gclm-/- mice show increased 
amounts of ROS and DNA damage that is accompanied by upregulation of Tp53 and p21 (Chen et 
al., 2009), these mice do not develop tumors spontaneously. 
 
6. Responses to episodes of oxidative stress in premalignant and malignant cells during 
the multiple stages of tumor development 
Whilst ROS/RNS can initiate carcinogenesis, they support the proliferation of initiated cells during 
the promotion and progression stages of tumorigenesis (Figure 4). However, oxidative stress can 
stimulate senescence or apoptosis in neoplastic cells during all stages of tumorigenesis, including 
anchorage-independent growth and metastasis. It is also recognised that GSH levels and TXN 
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and/or TXNRD are commonly increased in many cancer cells, presumably to combat the high ROS 
burden, and that this is associated with poor prognosis (Benhar et al., 2016). 
 
6a) ROS production is heightened in malignant disease 
Cancer cells contain higher levels of ROS than normal cells, and this sustains the phenotype. 
Sources of increased ROS production in tumor cells have been attributed to oncogene- and/or 
damage-stimulated production of: i) O2– by mitochondria, associated with altered assembly of the 
electron transport chain, hypoxia or anchorage-independent growth; ii) O2– by NOX, associated 
with hyperproliferation or centrosome abnormalities; iii) H2O2 by 5-lipoxygenase, associated with cell 
mobility; iv) H2O2 within the ER, associated with protein folding (Arnandis et al., 2018; Raimondi et 
al., 2020; Reczek et al., 2017; Zhou et al., 2014). Examples of oncogenes that increase ROS 
production include: a) Ras that alters mitochondrial metabolism, decreases mitochondrial membrane 
potential, and activates NOX2 and/or NOX4; b) Ras-related C3 botulinum toxin substrate 1 (Rac1) 
that activates NOX1; c) STAT3 that alters mitochondrial metabolism and activates NOX4; d) B-cell 
lymphoma 2 (BCL-2) that alters mitochondrial function; e) MYC that downregulates PGC-1α and 
suppresses mitochondrial biogenesis (Chong et al., 2018; Igelmann et al., 2019; Liou et al., 2016; 
Marcar et al., 2019; Satoh et al., 2017). Increased ROS levels in tumor cells may also result from 
loss of tumor suppressor-mediated regulation of antioxidant genes, such as decreased expression 
of SOD2, GPX1, SESN1 and SESN2 following inactivation of TP53 (Gorrini et al., 2013), or by 
posttranslational modifications, exemplified by acetylation of SOD2 (He et al., 2019), that confers 
upon antioxidant enzymes pro-oxidant properties.  Additionally, cancer cells may be stimulated to 
produce ROS by TNFα secreted by immune cells, or they may encounter ROS generated by immune 
cells recruited to the tumor. 
The increase in ROS in cancer cells stimulates proliferation and cell survival by blunting the 
activities of PTPs, PTEN (Figure 3), and MAPK phosphatases, thereby augmenting MAPK−ERK, 
PI3K−Akt and PKD−NF-κB signaling cascades, in a cell-specific manner (Moloney and Cotter, 2018). 
To support the proliferative benefits of high ROS levels whilst mitigating the risk of 
senescence/apoptosis, tumor cells upregulate antioxidant transcription factors and/or reprogram 
metabolism to increase NADPH and de novo synthesis of GSH by a variety of means (see below). 
Besides augmenting antioxidant systems to ameliorate oxidative stress, tumor cells may 
stimulate anti-apoptotic and pro-survival pathways. For example, breast cancer cells can utilize the 
redox-sensitive TRPA1 channel to activate Ca2+-signaling and so stimulate ERK and PI3K-PKB/Akt 
pathways, which in turn activate MCL-1 contributing to oxidative stress tolerance and drug 
resistance; moreover, NRF2 regulates expression of TRPA1, reinforcing the link between redox 
homeostasis and Ca2+-signaling (Takahashi et al., 2018), and extending the influence of NRF2 
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beyond redox. Perhaps also relevant, downstream of these events, clusters of proteins that 
participate in Ca2+ homeostasis are particularly sensitive to S-glutathionylation (Grek et al., 2013). 
 
6b) ROS production in premalignant cells mandates redox adjustments controlled by NRF2  
The view that ROS are necessary for tumor promotion is supported by the report that their 
pharmacological suppression using NAC or apocynin, attenuates lung adenocarcinoma in an 
oncogenic K-RASG12D−driven mouse model in which lung-specific knockout of Ikkα resulted in 
increased Nox2 expression and downregulation of Nrf2 (Song et al., 2018). Similarly, in an oncogenic 
B-RAFV600E−driven mouse melanoma model, knockout of Klf9 inhibited premalignant melanocyte 
hyperplasia because ROS production was diminished (Bagati et al., 2019), which is noteworthy 
because KLF9 suppresses NRF2 (Zucker et al., 2014). It is equally apparent that for malignant 
lesions to develop, levels of ROS should not exceed an upper ceiling. Thus, loss of antioxidant 
capacity as a consequence of knockout of Tigar, which impairs generation of NADPH, decreases 
development of premalignant pancreatic intraepithelial neoplasia (PanIN) lesions in a variety of K-
RASG12D−based mouse cancer models, including Trp53-/+ and Trp53R172H (Cheung et al., 2020). 
Recognition that tumorigenesis requires maintenance of high intracellular ROS levels raises 
questions about how cells harbouring mutations in oncogenes or tumor suppressor genes adjust 
their redox homeostasis so that the pro-tumorigenic effects of ROS are not quenched, whilst at the 
same time not succumbing to senescence or apoptosis. The Solt-Farber rat carcinogenesis model 
[induced by i.p. treatments with diethylnitrosamine (DEN) to initiate carcinogenesis, followed 2-
weeks later by two-thirds partial hepatectomy and dietary administration of 2-acetylaminofluorene to 
select growth of initiated cells] enables changes that accompany the different stages of cancer to be 
analysed, with the appearance in rat liver of physically discernible preneoplastic nodules, comprising 
as few as 20 hepatocytes, before the appearance of preneoplastic nodules/adenomas, which in turn 
precede formation of hepatocellular carcinomas  (Farber, 1984). Gene expression profiling revealed 
GCLC and GSTP1 are induced in early rat liver preneoplastic foci obtained 4 weeks after initiation, 
and robust induction of AKR7A1, GCLC, GCLM, GGT, GPX2, GSR, GSS, GSTA5, NQO1, TXNRD1 
and UGT1A6 occurs in persistent nodules obtained 10-20 weeks after initiation (Petrelli et al., 2014). 
Besides induction of GCLC and GSTP1, early nodules increase both glycolysis and the PPP by 
augmenting activities/protein levels of glucose transporter 1 GLUT1 (SLC2A1), hexokinase II (HK2), 
monocarboxylate transporter 4 (MCT4, SLC16A3, for lactate), G6PD and TIGAR, whilst at the same 
time suppressing OXPHOS by inducing the mitochondrial chaperone tumor necrosis factor receptor-
associated protein 1 (TRAP1) that binds complex II and IV of the electron transport chain and inhibits 
succinate dehydrogenase (Kowalik et al., 2016). Collectively, these findings suggest that antioxidant 
systems are upregulated and metabolism reconfigured in response to increases in ROS during the 
promotion and early progression stages of carcinogenesis. Interestingly, the changes in metabolism 
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in rat liver preneoplastic nodules broadly resemble the biochemical responses to acute oxidative 
stress in Fh1loxP/loxP mouse kidney epithelial cells (van der Reest et al., 2018). 
Many of the antioxidant genes upregulated in rat liver preneoplastic nodules are NRF2-target 
genes, suggesting NRF2 mediates adaptation to oncogene-stimulated oxidative stress. This 
interpretation is supported by the fact that NRF2-null rats subject to a modified Solt-Farber protocol 
(i.e. DEN followed by a choline-devoid and methionine-deficient diet) do not form preneoplastic 
nodules (Orru et al., 2018). The mechanism by which NRF2 transactivation activity is increased in 
preneoplastic nodules provides an insight into the severity of stress that initiated cells have to 
withstand. Thus, whilst NRF2 can be upregulated either by ROS inhibiting its repressor KEAP1, an 
E3 ubiquitin ligase substrate adaptor that controls NRF2 protein stability (Suzuki et al., 2019), or by 
oncogenes transcriptionally increasing NRF2 mRNA production (DeNicola et al., 2011), neither of 
these mechanisms are of principal importance in hepatic preneoplastic nodules. Rather, these 
nodules frequently contain gain-of-function mutations in NFE2L2 (Zavattari et al., 2015), indicating 
that permanent activation of NRF2 is necessary to allow initiated cells to survive and proliferate, 
rather than succumb to oxidative stress-driven apoptosis (Figure 5a). Most remarkably, it was 
estimated that approx. 70% of early preneoplastic nodules harboured ‘hot spot’ mutations in NFE2L2 
encoding amino acids within NRF2 that physically engage with the Kelch-repeat domain of KEAP1 
and are necessary for ubiquitylation of the transcription factor by CRLKEAP1 (Zavattari et al., 2015). 
Somatic mutations in NFE2L2 were also observed in approx. 60% of early and advanced 
hepatocellular carcinomas, respectively, suggesting genetic activation of NRF2 is required 
throughout promotion and progression of liver tumorigenesis.  
The hypothesis that formation of hepatic preneoplastic nodules in the rat requires NRF2 accords 
with mouse experiments in which livers from wildtype animals given a single i.p. dose of DEN all 
contained tumors after 9 months, compared to none from Nrf2-null mice (Ngo et al., 2017). This 
dependence on NRF2 also seems true of a number of other types of cancer. For example, the 
incidence of pancreatic cancer was markedly reduced in Nrf2-null mice relative to wildtype mice in 
a K-RasG12D−driven cancer model (DeNicola et al., 2011), and the incidence of lung tumors in Nrf2-
null mice was also modestly reduced relative to wild-type mice in urethane-initiated cancer (Bauer 
et al., 2011; Satoh et al., 2013). Similarly, knockout of Keap1 in mice, leading to hyperactivation of 
Nrf2, accelerated cholangiocarcinoma driven by K-RasG12D and Trp53R172H (Nabeshima et al., 2020).  
It is striking that the high frequency of somatic mutations in NFE2L2 observed in both rat liver 
preneoplastic nodules (Zavattari et al., 2015) and murine hepatoma (Ngo et al., 2017), which result 
in constitutive activation of NRF2, are clinically relevant as NFE2L2 or KEAP1 are frequently mutated 
in human tumors. In this context, it is imperative to recognise that there is no evidence that 
constitutive activation of NRF2, as for example observed in the Keap1FA/- mouse (in which the 
Keap1FA allele is hypomorphic (Taguchi et al., 2010)), is sufficient to trigger spontaneous 
tumorigenesis. Studies of Keap1FA/- mice have revealed constitutive upregulation of Nrf2 increases 
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proliferation of forestomach epithelium, but not cancer (Mitsuishi et al., 2012), and that Nrf2 mediated 
maximal transactivation of G6pd, Pgd and Me1 requires activation of the PI3K-Akt signaling 
pathway, which likely results in inhibition of GSK-3 and the failure to form the phosphodegron in the 
Neh6 domain of NRF2 that is recognised by β-TrCP (Chowdhry et al., 2013). Moreover, constitutive 
activation of NRF2, by deleting its Neh2 KEAP1-interaction domain does not increase the rate of 
primary tumor formation in a MMTV-rtTA::TetO-Her2 mouse cancer model (Fox et al., 2020). 
Collectively, these results imply that subsequent to a cancer initiating mutation(s), dysregulation of 
the NRF2-KEAP1 axis is a selective event under conditions of chronic oxidative stress, and so NRF2 
activation per se is not sufficient to stimulate cancer initiation. 
 
6c) NRF2-independent antioxidant mechanisms can also support early tumorigenesis 
The dependence on NRF2 for liver, pancreatic and lung cancer observed in rodents may not be true 
for other malignancies. For example, the incidence of tumors in Nrf2-null mice was not diminished 
relative to wildtype mice in benzo[a]pyrene-initiated gastric cancer (Ramos-Gomez et al., 2001), 
7,12-dimethylbenz[a]anthracene-initiated and 12-O-tetradecanoylphorbol-13-acetate−promoted 
skin cancer (Xu et al., 2006) or UV-initiated skin cancer (Knatko et al., 2015). In these cases, other 
members of the antioxidant transcription factor network may contribute to the putative resetting of 
redox homeostasis in early adenomas. Of possible relevance, NRF2-independent metabolic 
reprogramming occurs in rat preneoplastic nodules, as evidenced by upregulation of GLUT1, HK2, 
MCT4 and TIGAR in the lesions (Kowalik et al., 2016): HIF-1α may be responsible for upregulation 
of GLUT1, HK2 and MCT4; NF-κB may be responsible for upregulation of GLUT1; TP53 may be 
responsible for upregulation of TIGAR. 
In instances where NRF2 is not constitutively activated during the initiation of tumorigenesis, 
oncogenic tyrosine kinases may reprogram metabolism by phosphorylating the cancer-specific 
PKM2 isoform. In this scenario, phosphorylation of PKM2 causes it to adopt a dimeric rather than 
tetrameric quaternary structure, resulting in loss of pyruvate kinase activity and a relative block in 
the final steps of glycolysis (Li et al., 2014). In turn, spill-over of accumulated glucose-6-phosphate 
into the PPP increases NADPH generation by G6PDH, which enhances GSH- and TXN-based 
antioxidant defences (as indicated in Figure 1). Loss of pyruvate kinase activity also aids GSH 
synthesis. Specifically, increases in glyceraldehyde-3-phosphate, resulting from phosphorylation of 
PKM2, can be funnelled through the serine synthesis pathway, with the resulting serine being 
available to form glycine (from serine by serine hydroxymethyltransferase within the one-carbon 
pathway) and cysteine (from cystathionine by cystathionine lyase within the trans-sulfuration 
pathway), two of the amino acids used to synthesise GSH (Yang and Vousden, 2016); the supply of 
cysteine can be augmented by the cystine/glutamate antiporter SLC7A11, the expression of which 
can be increased by oncogenic Ras (Lim et al., 2019). Besides glycine and cysteine, GSH 
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biosynthesis requires a supply of glutamate, and this can be provided by the combined actions of 
the transporters ASCT2/SLC1A5 and SNAT2/SLC38A2 that import glutamine (Broer et al., 2019; 
Morotti et al., 2019) along with glutaminase that converts glutamine to glutamate (Mates et al., 2020). 
Importantly, both the glutamine transporters and glutaminase are upregulated in tumor cells through 
oncogene activation or hypoxia (Bott et al., 2015; Lukey et al., 2016; Morotti et al., 2019).  
Amongst 29 cancer types, significant positive selections for mutations in NFE2L2 and KEAP1 
occur in bladder, endometrium, oesophagus, head-neck, liver and lung (Martincorena et al., 2017). 
Somatic mutations in NFE2L2 or KEAP1 are not however universal features of malignant disease, 
and so other mechanisms of NRF2 activation as well as NRF2-independent antioxidant systems 
likely contribute to adaptation to oxidative stress that accompanies tumorigenesis in certain types of 
cancer. Possibly, NRF2 is only genetically upregulated when certain oncogenes are activated or 
tumor suppressor genes lost. 
 
6d) Supply of exogenous antioxidants and diminution of endogenous antioxidants 
modulates early tumorigenesis 
Using Cre-inducible Kras2LSL- and BrafCA-based lung cancer models, it has been found that 
administration of NAC in the drinking water, or vitamin E in the diet, one week after initiation of 
tumorigenesis by expressing K-RASG12D or B-RAFV600E, significantly increased tumor burden (Sayin 
et al., 2014). This was attributed to the ability of NAC and vitamin E to diminish oxidative stress, 
decrease DNA damage and blunt activation of wild-type TP53. However, it is noteworthy that many 
genes that were downregulated by the NAC and vitamin E treatments are NRF2 transcriptional 
targets, and the extent to which these antioxidants influenced the activity of other members of the 
antioxidant transcription factor network was not investigated. Nevertheless, it is interesting that NAC 
and vitamin E both support lung tumorigenesis, suggesting that maintenance of redox status 
throughout the cell is important during early tumor progression. 
      Experiments using the MMTV-PyMT spontaneous mammary tumor mouse model showed that 
in order for disease to proceed, cancer cells require GSH to maintain their appropriate redox status 
during the early stages of tumorigenesis, though this does not necessarily involve NRF2. Thus, 
immediately after weaning, administration of the GCL inhibitor buthionine-(S,R)-sulfoximine (BSO) 
to MMTV-PyMT mice greatly delayed tumor onset, suggesting that a critical threshold of GSH is 
required to support initiation of cancer (Harris et al., 2015). By contrast, when BSO was administered 
to MMTV-PyMT mice once mammary tumors had become physically evident, it was unable to delay 
tumor progression. Failure of BSO to inhibit later tumor progression is likely a consequence of 
malignant transformation causing overexpression of both CD44 and TXNRD1, which in turn allowed 
tumor cells to compensate for loss of GSH by increasing cystine uptake via xCT and by better 
utilising TXN. Notably, when cancer cells were treated with a combination of BSO plus the xCT 
inhibitor sulfasalazine, or a combination of BSO plus the TXNRD1 inhibitor Auranofin, a striking 
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increase in cell death was observed, dependent on ROS. After tumors were established, treatment 
of MMTV-PyMT mice with BSO plus sulfasalazine markedly reduced tumour growth in vivo. 
Together, these results suggest that during initiation of cancer the GSH antioxidant system is 
principally responsible for attenuation of ROS that might trigger cell death, whereas after initiation, 
GSH and TXN synergistically support tumor cell survival. Whilst NRF2 controls GSH homeostasis, 
other members of the antioxidant transcription factor network may also contribute to maintaining high 
GSH and TXN levels (see Table 1). 
 
6e) Influence of ROS and RNS on the tumor microenvironment during progression of disease  
Cancer progression requires shaping the tumor microenvironment (TME). This involves reciprocal 
cross-talk between neoplastic cells and the TME that includes ROS/RNS. The functions of cancer-
associated fibroblasts (CAFs), tumor-associated macrophages (TAMs) and T cells are all affected 
by ROS/RNS within the TME. Thus, both CAFs and TAMs “cooperate” with neoplastic cells by 
contributing to a developmental program called epithelial-to-mesenchymal transition (EMT) by 
helping to remodel the extracellular matrix (ECM), thereby stimulating tumor cell proliferation, tumor 
angiogenesis, immunosuppression and tumor invasion (Nieto et al., 2016). Additionally, regulatory 
T (Treg) cells, which are critical for preventing autoimmunity, suppress effective tumor immunity; the 
presence of intratumoral Treg cells is often associated with poor prognosis (Beyer and Schultze, 
2006). The TME also harbors specific cytotoxic CD8+ T cells. Although expected to support the 
immune destruction of tumor cells, CD8+ T cells often express co-inhibitory receptors such as 
programmed death-1 (PD-1), and are considered terminally differentiated or “exhausted”. 
Conversely, the recently identified subset of stem cell-like tumor-infiltrating PD-1+ TCF1+ CD8+T 
cells contribute to limiting tumor progression in response to immunotherapy (Held et al., 2019). 
In terms of the effects of ROS in the TME, chronic oxidative stress resulting from JunD 
inactivation has been shown to promote myofibroblast differentiation in stroma associated with 
mammary adenocarcinomas through activation of HIF-1α and increased production of the CXCL12 
chemokine, which together stimulate tumor growth and vascular remodelling, and shorten survival 
(Toullec et al., 2010). It is therefore of interest that in stromal remodeling associated with progression 
of prostate cancer, transforming growth factor-beta (TGF-β)−stimulated fibroblast-to-myofibroblast 
differentiation is preceded by induction of NOX4, increased production of ROS and phosphorylation 
of JNK, and is accompanied by downregulation of the selenoproteins GPX3 and TXNRD1 (Sampson 
et al., 2011). By contrast, selenium supplementation decreases ROS levels and inhibits fibroblast 
differentiation into myofibroblasts, suggesting ROS drive trans-differentiation of stromal cells. In 
addition, cancer cell-derived H2O2 causes metabolic changes in CAFs, including increased glucose 
uptake, decreased mitochondrial activity, and increased ROS production, whereas the presence of 
CAFs causes reciprocal metabolic changes in the adjacent cancer cells, such as decreased glucose 
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uptake and increased mitochondrial activity (Martinez-Outschoorn et al., 2011). These metabolic 
alterations can be abrogated by addition of CAT, implicating H2O2 as the signaling molecule. 
ROS also contribute to the pro-tumorigenenic, anti-inflammatory and immunosuppressive 
properties of TAMs that favor tumor progression. In malignant melanoma, production by TAMs of 
mitochondrial ROS stimulates MAPK/ERK activity leading to secretion of TNFα, which promotes 
tumor cell invasion (Lin et al., 2013). When exposed to cell-free tumor fluid, peritoneal macrophages 
that exist in the classically active pro-inflammatory (M1) phenotype adopt an alternatively activated 
(M2) phenotype associated with immunosuppression (Ghosh et al., 2015). Furthermore, ROS and 
RNS produced by TAMs suppress T cell functions (Ghosh et al., 2015; Hamilton et al., 2014). It has 
been shown that in mice, O2– generated by Nox2 stimulates Treg cells to dampen T cell-mediated 
inflammation (Kraaij et al., 2010). It is not clear if this process is recapitulated in TAMs, but if so, it 
would further contribute to TAM-mediated immunosuppression. Notably, using oncogene-initiated 
zebrafish models of glioma, it was shown that TAMs engage in ATP-mediated interactions with pre-
neoplastic cells at a very early stage of tumor development, and that depletion of TAMs or reducing 
the number of these interactions significantly impairs the proliferation of neoplastic cells (Chia et al., 
2019; Chia et al., 2018). Whether or not ROS play a role in these interactions is currently unknown, 
although this is a distinct possibility considering that oncogene activation stimulates ROS production. 
Myeloid-derived suppressor cells (MDSCs) induce antigen-specific CD8+ T-cell tolerance, which 
constitutes a major mechanism of tumor escape from immune surveillance. Tumor-infiltrating 
MDSCs produce ONOO–, which nitrates Tyr residues in the T-cell receptor (TCR)-CD8 complex, 
thus disrupting binding of specific peptide-major histocompatibility complex (pMHC) dimers to the 
CD8+ T cell (Nagaraj et al., 2007); critically, use of a ONOO– scavenger abolished MDSC-induced T 
cell tolerance. Treatment of cancer cells with ONOO– inhibited binding of processed peptides to 
cancer cell-associated MHC, resulting in resistance to antigen-specific cytotoxic T cells, whereas 
inhibition of ONOO– production improved immunotherapy (Lu et al., 2011), implicating ONOO– as a 
critical regulator of the effects of cytotoxic T cells. Overall, in myeloid cells, mitochondria, NOX, 
arginase-1 and NOS2 all contribute to ROS production, where in addition to O2–, cooperation 
between arginase-1 and NOS2 results in the formation of ONOO–. The combined effect of ROS and 
RNS leads to T cell suppression, tolerance and resistance to cytotoxic T cells. 
In T cells, ROS play a dual role. Mitochondrial ROS are essential for T cell activation (Kaminski 
et al., 2012; Sena et al., 2013), but ROS in the TME can lead to T cell hypo-responsiveness 
(Cemerski et al., 2002). In tumor-infiltrating T cells, which are functionally impaired, mitochondrial 
activity is compromised (Scharping et al., 2016; Siska et al., 2017), but can be rescued by increasing 
mitochondrial biogenesis (Scharping et al., 2016), using mitochondrial ROS scavengers (Siska et 
al., 2017), or by overexpression of CAT (Ligtenberg et al., 2016). Critically, these manipulations also 
restore the antitumor activity of T cells, further demonstrating the importance of mitochondrial activity 
and balanced ROS production for T cell function. Interestingly, enhanced mitochondrial activity and 
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ROS production synergize with the tumoricidal activity of PD-1 blockade by expansion of 
effector/memory T cells (Chamoto et al., 2017). In addition, production of ONOO– in the TME inhibits 
T cell migration into the tumor by nitrating and inactivating the chemokine CCL2 (Molon et al., 2011), 
which is a chemoattractant for myeloid cells, activated T cells, and natural killer (NK) cells. 
Although information is limited, it appears that unlike most other immune cells in the TME, 
neutrophils preserve their anti-tumor activity under oxidative stress conditions, which could be 
attributed to their high ROS-producing potential. Thus, tumor-associated neutrophils have been 
shown to suppress the expansion of the pro-tumorigenic IL-17+ γδ T cells via NOX2-mediated O2– 
production (Mensurado et al., 2018). Moreover, IL-17-producing γδ T cells have lower GSH levels 
than their IFNγ-producing γδ counterparts, providing an explanation for the exquisite sensitivity of IL-
17+ γδ T cells to O2– and H2O2. Importantly, Vδ1+ γδ T cells, the main γδ T cell subset that produces 
IL-17 in human tumors, also have low GSH levels in comparison with other human T cell subsets, 
and are sensitive to ROS, suggesting the clinical relevance of these findings. 
These findings indicate that increases in ROS/RNS stimulate changes in the TME that support 
tumorigenesis by altering the functions of CAFs and TAMs, and at the same time they stimulate 
changes in T cells that might suppress immune responses to tumor cells. 
 
6f) EMT during cancer progression entails marked changes in redox status and tumor cell 
heterogeneity 
For early neoplastic cells to progress to malignant carcinomas, they typically exploit EMT in order to 
increase mobility and invade adjacent stroma (Nieto et al., 2016), which can confer tumor-initiating 
potential and cancer stem cell properties, that enables them to form new foci when seeded 
elsewhere (San Juan et al., 2019). Activation of EMT is dictated by the tissue in which the neoplastic 
cell originated, as well as by CAFs and TAMs in their microenvironment (El-Kenawi et al., 2019), 
and thus provides major roles for Wnt, TGF-β and Notch ligands, along with various growth factors 
(Chaffer et al., 2016) and ROS (Jiang et al., 2017), in initiating the program. It is a highly-coordinated 
process during which early epithelial-like neoplastic cells acquire mesenchymal-like features, 
accompanied by restructuring of the composition of ECM proteins (Dongre and Weinberg, 2019). 
Pioneering studies by Mina Bissell and colleagues revealed that initiation of EMT in murine SCp2 
mammary epithelial cells upon exposure to MMP-3 involved expression of an alternatively spliced 
form of Rac1, called Rac1b, which by stimulating mitochondrial ROS production caused induction of 
vimentin, increased cell migration and genomic instability (Radisky et al., 2005). These workers also 
discovered that the ability of MMP-3 to initiate EMT in SCp2 cells could be blocked by treatment with 
the antioxidant NAC or by ectopic expression of SOD2, but not by ectopic SOD1 or CAT, results 
suggesting that mitochondrially-produced ROS are required during the very early stages of EMT. It 
is likely that SOD2 contributes to EMT, insofar as when it is overexpressed in MCF-7 cells (which 
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exhibit an epithelial-like phenotype) it becomes acetylated on Lys-68, probably catalysed by the 
GCN5L1 acetyl transferase, with the resulting post-translationally-modified enzyme displaying pro-
oxidant rather than antioxidant activity (He et al., 2019); it is currently envisaged that SOD2K68Ac 
increases ROS production, which in turn activates HIF-2α, producing a cancer stem cell like 
phenotype that includes expression of Oct4 and Nanog. 
EMT in neoplastic cells is directed by the master regulator EMT-activating transcription factors 
(EMT-TFs) SNAIL (also called SNAI1), SLUG (also called SNAI2), TWIST1, TWIST2, ZEB1 and 
ZEB2, which are considered key drivers of tumor progression as they transactivate genes associated 
with a mesenchymal state and repress genes associated with an epithelial state (Stemmler et al., 
2019). Interestingly, EMT-TFs differ in their relative abilities to induce mesenchymal-associated 
genes and repress epithelial-associated genes. In some settings, SNAIL and ZEB1 only weakly 
induce mesenchymal-associated genes, whilst strongly repressing epithelial-associated genes, 
whereas TWIST1 exerts the opposite effects (Chaffer et al., 2016). Expression of SNAIL, SLUG, 
TWIST1, ZEB1 and ZEB2 is subject to complex control mechanisms, including transcriptional 
regulation by AP1, HIF-1α, NF-κB and TP53 (Figure 5b), a fact that implies the ability of EMT-TFs 
to induce mesenchymal-related genes and repress epithelial-related genes is controlled in part by 
redox signalling (Jiang et al., 2017); moreover, HSF1, which is also redox regulated, supports EMT 
(Powell et al., 2016; Xi et al., 2012). Consistent with the notion that redox influences EMT, this 
process can be initiated in SCp2 cells by MMP-3, which elicits a Rac1b-stimulated production of 
ROS, that leads to activation of NF-κB, and in turn the upregulation of SNAIL (Cichon and Radisky, 
2014).  
As mentioned above, TGF-β regulates EMT-TFs in transformed cells and it is inextricably 
interrelated with redox. In this situation, binding of TGF-β to its cell-surface receptor, TGF-β receptor 
type 1 (TGFβR1), or TGFβR2, causes phosphorylation of SMAD2 and SMAD3 that, in turn, trimerize 
with SMAD4 and, following nuclear translocation, positively regulate SNAIL, SLUG, TWIST1 and 
ZEB1 (Massague, 2012). Induction of EMT-TFs by TGF-β signaling is heightened considerably by 
input from the RAS-MAPK pathway (David and Massague, 2018). Critically, from a redox 
perspective, activation of TGF-β signaling induces NOX4 and represses CAT, GCLC, GCLM, GPX3 
and TXNRD1 (Liu et al., 2012; Sampson et al., 2011), with the resulting increase in ROS stimulating 
trans-differentiation and cell proliferation. 
Whilst ROS are necessary to initiate EMT, it is unclear to what extent they are required to 
maintain a mesenchymal phenotype. Consistent with ROS playing a role in initiation of EMT, 
treatment with the antioxidant NAC can antagonise stimulation of EMT by TGF-β in various cells 
types, including murine AML12 hepatocytes (Kim et al., 2019), human ARPE-19 adult retinal pigment 
epithelial cells (Yang et al., 2020) and human HCC4006 lung epithelial cells (Haley et al., 2019). Possibly 
more surprising is that in a stably gefitinib-resistant human PC-9 non-small cell lung cancer cell line, 
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treatment with NAC has been reported to increase an epithelial-phenotype and decrease the 
mesenchymal-phenotype (Li et al., 2020), suggesting a relative absence of ROS may stimulate 
mesenchymal-to-epithelial transition (MET). In contrast, oxidative stress in murine B16F10 melanoma 
cells, caused by inhibition of GSR1, has been reported to decrease EMT (Li et al., 2018), and in oral 
squamous cell carcinomas in which Aurora kinase A (AURKA) is aberrantly expressed, knockdown of 
AURKA increased ROS levels and inhibited EMT (Dawei et al., 2018). Collectively, these data suggest 
that the influence of ROS on a mesenchymal phenotype is dose- and time-dependent, with thresholds 
controlling the triggering of senescence/apoptosis being of critical importance. 
One important question is whether oxidative stress contributes to the maintenance of the cancer 
mesenchymal cell phenotype. The fact that EMT is not a binary process, and is reversible (Chaffer 
et al., 2016), represents a confounding factor when interpreting the literature. Comparisons between 
epithelial-like human MCF-7 breast cancer cells and mesenchymal-like human MDA-MB-231 breast 
cancer cells revealed that the latter produce substantially higher levels of H2O2 than the former 
(Lunetti et al., 2019). Moreover, HCC4006, A549 and H538 non-small cell lung cancer cell lines 
treated with TGF-β to induce a mesenchymal phenotype produce substantially higher levels of ROS 
than their non-treated epithelial counterparts (Haley et al., 2019). By contrast, breast cancer stem 
cells (BCSCs) with an epithelial-type morphology (i.e., E-BCSCs) have been reported to generate 
high levels of ROS, exhibit metabolic flexibility and possess heightened NRF2-regulated antioxidant 
defences necessary for survival, whereas BCSCs with a mesenchymal-type morphology (i.e., M-
BCSCs) have low ROS levels, are dependent on glycolysis for energy, do not have high antioxidant 
defences, and do not require NRF2 for survival (Luo et al., 2018). By targeting these biochemical 
differences, it was found that M-BCSCs convert to E-BCSCs upon treatment with the glycolysis 
inhibitor 2-deoxyglucose (2-DG), which also increases ROS levels; the triggering of MET in M-
BCSCs by 2-DG is thought to occur by activation of the AMPK−HIF-1α axis along with NRF2 (Luo 
et al., 2018). Remarkably, treatment of M-BCSCs with NAC antagonised the ability of 2-DG to 
stimulate MET, whilst treatment of E-BCSCs with 2-DG and the TXNRD inhibitor Auranofin 
diminished their proliferation and/or self-renewal. Also, knockdown of NRF2 decreased E-BCSC 
numbers but had no effect on the number of M-BCSCs. 
The above findings indicate that the effects of ROS on EMT are variable and probably reflect 
cancer cell-type specific and/or TME-dependent differences. It is plausible that this variability reflects 
heterogeneity in tumor cells, caused by factors controlling transition between epithelial and 
mesenchymal states. In this context, it is notable that NRF2 supports epithelial and hybrid 
epithelial/mesenchymal phenotypes, and knockout of NRF2 allows a mesenchymal phenotype to 
become established (Bocci et al., 2019; Zhou et al., 2016), though the degree to which this 
represents cause and effect is uncertain. 
 
6g) Adaptation to oxidative stress during anchorage-independent growth 
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During the first stage of the metastatic cascade (see (Nieto et al., 2016)), resistance of tumor cells 
to death triggered by their detachment from the ECM and loss of integrin-mediated signaling, 
principally anoikis, is necessary for progression of tumorigenesis. Most importantly, ECM 
detachment results in catastrophic metabolic changes including defective glucose uptake, 
attenuated PPP flux and reduced ATP levels (Hawk and Schafer, 2018) that limits the metabolic 
flexibility of detached cells and renders them susceptible to oxidative stress. Indeed, detachment of 
non-transformed human MCF-10A breast epithelial cells increases ROS and decreases GSH due to 
diminished PPP flux (Schafer et al., 2009), whilst detachment of human A549 non-small cell lung 
cancer cells increases H2O2 and decreases NADPH levels (Jeon et al., 2012).  
Cancer cells can employ a wide variety of mechanisms to avoid anoikis, including triggering of 
EMT, integrin switching, growth factor overexpression, activating pro-survival signaling, activating 
oncogenes, and adapting metabolism to ameliorate stress (Paoli et al., 2013). In the last category, 
there is ample evidence that upregulation of antioxidant genes blunts anoikis and supports 
anchorage-independent growth. However, unlike adaptation to oxidative stress during initiation of 
tumorigenesis, which often involves somatic mutation of NFE2L2 or KEAP1, adaptation during 
anchorage-independent cell growth involves rerouting metabolism to increase generation of NADPH 
without resorting to constitutive activation of antioxidant genes. In three-dimensional (3D) luminal-
filling experiments, MCF-10A cells that lack matrix attachment are unable to form acinar structures 
because they succumb to anoikis, but this can be rescued by certain oncogenes including ERBB2. 
By virtue of the fact it prevents downregulation of the EGFR and maintains the PI3K pathway after 
matrix detachment, overexpression of ERBB2 enables MCF-10A cells to form acinar structures, 
thereby increasing glucose uptake and restoring ATP levels (Schafer et al., 2009). This increase in 
glucose uptake was found to be funnelled down the PPP to enhance NADPH production by G6PD 
and increase GSH levels that might suppress ROS induced cell death; this resembles, at least in 
part, adaptation to acute oxidative stress in normal cells (see Figure 1). Also of note, this increase 
in antioxidant status prevented ROS from inhibiting fatty acid oxidation and so maintained 
intracellular ATP levels sufficiently to avert metabolic crisis. 
Matrix detachment produces energy stress that activates AMPK, which also contributes to 
increased production of NADPH (Jeon et al., 2012). In A549 cells, matrix detachment by 
phosphorylating and inhibiting acetyl-CoA carboxylase (ACC1 and ACC2), triggered AMPK 
activation to provide protection against oxidative stress, ultimately decreasing fatty acid synthesis 
and increasing fatty acid oxidation (Jeon et al., 2012). This blunting of fatty acid synthesis by 
inhibition of ACC1/2 conserves NADPH, making it available to support antioxidant defences, and so 
counter oxidative stress that would otherwise trigger cell death. Of note, knockdown of ACC1 in A549 
cells blocked the increase in H2O2 and decreased the NADP+/NADPH ratio that occurs following 
matrix detachment, thus supporting such an interpretation.  
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Like MCF-10A and A549 cells, anchorage-independent growth of H460 lung cancer cells also 
requires increased generation of NADPH to mitigate oxidative stress that might limit tumor 
progression. In this case however, ROS were found to accumulate primarily in mitochondria, and 
this was mitigated by increased generation of NADPH through reductive glutamine metabolism, 
which is normally only observed during hypoxia in a HIF-1α−dependent manner. Thus, in H460 
spheroids, reductive carboxylation of α-KG formed from glutamine is catalysed by IDH1 in the 
cytoplasm, independently of HIF-1α and hypoxia; this provides isocitrate, which is then imported into 
mitochondria where it is oxidised back to α-KG by IDH2, thereby providing reducing equivalents to 
fortify mitochondrial ROS defences (Jiang et al., 2016). During this process, cytoplasmic NADPH 
depletion resulting from reduction of α-KG by IDH1 is restored by the PPP, and so reducing 
equivalents from the PPP are transferred to mitochondria (Figure 6a). Clustering of detached tumor 
cells represents another strategy that aids anchorage-independent growth, because clustering 
stimulates HIF-1α−mediated mitophagy that limits ROS production and in so doing increases 
dependence on glycolysis and reductive carboxylation of glutamine; this forced use of OXPHOS 
decreases survival of detached cells (Labuschagne et al., 2019). 
More recently it was observed that maintenance of fatty acid synthase (FASN) activity in mouse 
embryonic fibroblast (MEF) cells expressing oncogenic K-RASG12D, HER2(A775_G776insYVMA) or 
the PyMT antigen is an absolute requirement during the switch from 2D to 3D growth in colony 
formation assays (Bueno et al., 2019). Pharmacological or genetic inhibition of FASN in MEF lines 
harbouring these oncogenes prevented colony formation. Failure to grow upon inhibition/knockout 
of FASN was attributed to perturbation of glycolysis and mitochondrial function. In particular, 
inhibition/knockout of FASN caused a decrease in IDH1-catalysed reductive carboxylation due to 
accumulation of citrate/isocitrate. This occurred because loss of FASN activity caused a build-up of 
acetyl-CoA which inhibited ATP-citrate lyase, thereby increasing citrate. The inhibition of IDH1 by 
citrate/isocitrate resulted in an increase in mitochondrial ROS, decreased assembly of complex I of 
the electron transport chain into functional super-complexes and a stalling of respiration. This is 
consistent with the notion that IDH1 is necessary for anchor-independent growth and tumorigenesis. 
A common theme that emerges from studies into anchorage-independent cell growth is that 
treatment with antioxidants, such as NAC or Trolox (a water-soluble vitamin E derivative), can both 
rescue the metabolic defects caused by ECM deprivation and increase growth in soft agar (Bueno 
et al., 2019; Jeon et al., 2012; Schafer et al., 2009). This raises the question of whether antioxidants 
promote transformation of mammary epithelial cells. Consistent with this, upregulation of HO-1 
protects against anoikis (Dey et al., 2015) and conversely, knockdown of NQO1 renders non-small 
cell lung cancer cells more susceptible to anoikis (Madajewski et al., 2016). 
 
6h) Oxidative stress represents a barrier to the metastatic spread of cancer 
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For tumor cells to metastasise they need to undergo intravasation in order to enter the bloodstream, 
where they are exposed to a substantially higher O2 tension than their site of origin. They may also 
experience oxidative stress whilst migrating into the circulation, or before they extravasate to invade 
a distant organ (Nieto et al., 2016). This phase of tumorigenesis is inefficient, and its success 
requires plasticity on the part of the metastasising cell. Experiments in mice involving subcutaneous 
or intravenous injection of efficient metastasising melanomas revealed that the subcutaneous route 
of administration was substantially more effective than the latter in forming tumors (Piskounova et 
al., 2015). As ROS and GSSG levels were higher in circulating melanoma cells and metastatic 
melanoma cells than in subcutaneous tumors, and treatment with NAC increased the frequency of 
melanomas in the blood and the metastatic disease burden, it was reasoned the bloodstream is a 
pro-oxidant environment that provoked oxidative stress and impeded metastasis. Consistent with 
this view, metastatic nodules in the liver, pancreas and lung from injected melanoma cells had higher 
levels of NADPH and NADP+ than did subcutaneous tumors, and this was associated with increased 
contribution of glucose to serine and glycine levels, augmented folate pathway activity and an over-
abundance of the mitochondrial ALDH1L2, and to a lesser extent cytoplasmic MTHFD1 (Figure 6b) 
(reviewed by (Ducker and Rabinowitz, 2017)). Thus, upregulation of these NADPH-generating 
enzymes may allow metastasising tumor cells to survive in the bloodstream and invade distant 
organs (Piskounova et al., 2015). These authors also recognised that folate metabolism was not 
solely responsible for NADPH generation that drives metastasis, and that the PPP and malate 
pathways likely also contribute. 
Whilst high ROS levels limit metastatic spread of melanoma cells, those that are successful 
appear to be selected by their ability to use lactate as an energy source. This is possible because of 
heterogeneity in expression of the lactate transporter MCT1 (SLC16A1) in tumor cells (Tasdogan et 
al., 2020). Antagonism of MCT1 with the selective inhibitor AZD3965, shRNA knockdown, or gene 
editing, has been shown to decrease the number of circulating melanoma cells and metastatic 
tumors arising from subcutaneous transplantation of melanoma cells, a process rescuable by 
treatment with NAC. Inhibition of MCT1 in melanoma cells increased ROS levels, decreased the 
abundance of GSH, NADPH and flux through the oxidative arm of the PPP. It was concluded that 
inhibition of MCT1 would decrease flux through the oxidative arm of the PPP because lactate uptake 
is linked with proton flux, and so the increase in pH would increase glycolysis by activating 
phosphofructokinase and suppressing G6PD activity. 
 
6i) Evidence that ROS have diverse effects on different forms of metastatic disease, and the 
conundrum posed by antioxidants 
Conflicting data exist relating to the effects of oxidative stress on metastasis. This likely reflects 
heterogeneity in redox thresholds for pathways controlling proliferation, mobility and survival in 
different tumor cells. These are presumably dictated by the source of ROS and the subcellular 
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compartments affected, influenced by variables including the: oncogenes activated; status of 
members of the antioxidant transcription factor network; extent to which neoplastic cells toggle 
between epithelial and mesenchymal phenotypes. In the latter case, oscillation between EMT and 
MET enables invading tumor cells to adapt to new environments (Dongre and Weinberg, 2019; Lu 
and Kang, 2019). It is becoming clear that the ability of cancer cells to adopt a hybrid 
epithelial/mesenchymal status is controlled by a numer of “phenotypic stability factors” such as 
grainyhead-like 2 (GRHL2), ovo-like zinc finger 2 (OVOL2), ∆Np63α and NUMB, which stabilise such 
hybrid phenotypes (Aljagthmi et al., 2019; Bocci et al., 2017; He et al., 2020; Wu et al., 2017), and it 
could be hypothesised that the plasticity conferred by GRHL2, OVOL2, ∆Np63α and NUMB is pivotal 
in determining the ability of tumor cells to withstand oxidative stress. 
As discussed above, premalignant cells must adapt to the added ROS burden caused by 
activated oncogenes which places extra demands on their antioxidant systems. Consistent with this, 
knockout of antioxidant defences provided by Nrf2 or Tigar markedly decreases development of 
PanIN lesions in K-RASG12D cancer models (Cheung et al., 2020; DeNicola et al., 2011). 
Counterintuitively, whilst high ROS levels can impede progression of tumorigenesis, there are 
examples where they actually enhance metastasis. Thus, in the K-RASG12D pancreatic cancer model, 
whilst knockout of Nrf2 or Tigar delays the appearance of PanIN lesions, their loss also increases 
metastasis to the lung and other organs, with resulting tumors having high ROS levels and exhibiting 
mesenchymal characteristics (Cheung et al., 2020). The increase in metastatic potential of 
KrasG12D/+;Tigar-/- tumors was associated with activation of ERK signaling, attributed to 
downregulation of the dual-specificity phosphatase DUSP6. Ectopic expression of DUSP6 in Tigar-
null cells was found to inhibit migration and the mesenchymal phenotype, as did treatment with NAC 
or the mitochondrially-targeted antioxidant mito-TEMPO. In tail vein injection assays, treatment with 
NAC inhibited colonisation of the lung by Tigar-null pancreatic tumor cells. Besides the ability of 
antioxidants to inhibit metastatic capabilities of Tigar-null pancreatic tumor cells, mito-TEMPO 
prevented lung metastasis of orthotopically-injected MDA-MB-231 breast cancer cells in SCID mice 
(Porporato et al., 2014) and transgenic overexpression of mitochondrially-targeted CAT diminished 
invasive breast cancer in MMTV-PyMT mice (Goh et al., 2011). Collectively, these findings suggest 
that antioxidants might trigger reductive stress in certain types of tumor cell. 
In contrast to the observation that NAC and mito-TEMPO suppress metastatic spread of 
pancreatic tumors, an increasing literature indicates that antioxidants can support metastasis of 
melanoma and lung tumors. In mouse experiments, NAC and Trolox increase metastasis to the lung 
of melanoma cells harboring oncogenic B-RAFV600E with melanocyte-specific loss of Pten expression 
(Bagati et al., 2019; Le Gal et al., 2015) as well as human-derived metastasizing melanoma cells 
(Piskounova et al., 2015). Also, NAC and vitamin E increase metastasis to the liver, kidney, heart 
and rib cage of lung cells harboring oncogenic K-RASG12D (Wiel et al., 2019). 
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The ability of NAC and vitamin E to increase metastasis of K-RASG12D−driven lung tumors was 
attributed to the ability of antioxidants to reduce the levels of ROS and free heme, thereby stabilising 
BACH1, which in turn transcriptionally activated Hk2 and Gapdh and increased glucose uptake, 
glycolysis and lactate secretion by Mct1 (Wiel et al., 2019). Importantly, BACH1 has been reported 
to be a master regulator of metastasis (Lee et al., 2013), and upregulates expression of metastasis-
associated genes such as MMP1, MMP3, CXCR4, CTGF, PGK2 and ROBO1 (Liang et al., 2012). 
Also, BACH1 can suppress mitochondrial activity by repressing expression of the electron transport 
chain genes ATP5D, COX15, UQCRC1, ATP5J, SLC25A22 and TIMM8B, and decrease glycolysis 
and the TCA cycle by increasing expression of pyruvate dehydrogenase kinase, thus inactivating 
phosphorylation of pyruvate dehydrogenase (Lee et al., 2019). Similar to the effects of antioxidants 
on K-RASG12D−driven lung tumorigenesis, it has been proposed that loss of Keap1 increases K-
RASG12D−driven tumor metastasis via activation of Bach1. Thus knockdown of Keap1 in 
KrasG12D/+;Trp53-/- tumors increased metastasis, but in this case the increase in Bach1 upon 
knockdown of Keap1 was due to Nrf2-mediated induction of Hmox1, which increased Bach1 stability 
by degrading heme (Lignitto et al., 2019). Similarly, in human HT1080 fibrosarcoma cells that 
harbour N-RAS and IDH1 mutations, ATF4-mediated induction of HMOX1 increased metastatic 
potential (Dey et al., 2015). Taken together, these observations suggest that administration of 
antioxidants can substantially affect the metastatic potential of cancer, but that this is probably 
influenced by tumor type and organ subject to colonisation.  
Dormant cancer cells that remain following therapy, and those that give rise to recurrent drug-
resistant tumours during relapse, have to withstand oxidative stress resulting from their inability to 
utilise glucose as an energy source resulting in a switch to fatty acid β-oxidation. In particular, 
inhibitors of the receptor tyrosine kinase-RAS-MAPK pathway increase ROS (Krall et al., 2017), as 
does loss of oncogenic MYC, RAS and Neu/Her2 signaling (Havas et al., 2017). In an MMTV-
rtTA::TetO-Her2 mouse model, the small population of residual cells that survived in tumors following 
loss of oncogenic Her2 were found to upregulate Nrf2 in response to increased ROS (Fox et al., 
2020). Moreover, constitutive activation of Nrf2 accelerated tumor recurrence, and knockdown of 
Nrf2 diminished recurrent tumor growth in vivo. Understandably, these are highly prescriptive models 
that for experimental reasons are limited to just several types of cancer. Because of the added ROS 
burden incurred during initiation, progression and metastasis it is unclear how dormant and recurrent 
cancer cells with NRF2 already upregulated adapt to oxidative stress during and after chemotherapy. 
 
7. Therapeutic value of manipulating redox status in tumour cells 
Misunderstandings about how oxidative stress influences different stages of tumorigenesis is 
emphasised by the poor responses of at-risk patients given antioxidant therapy (Gill et al., 2016; 
Goodman et al., 2011). In animal carcinogenesis models, induction of endogenous antioxidant and 
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detoxification systems by cancer chemopreventive agents confers protection against initiation of 
carcinogenesis caused by the subsequent exposure to chemical carcinogens (Wattenberg, 1985). 
However, administration of antioxidants per se may accelerate the later stages of certain types of 
cancer (Bagati et al., 2019; Wiel et al., 2019), results that support the notion that antioxidants have 
distinct effects on different stages of tumorigenesis and in a tumor type-specific fashion. 
Like vitamin D, vitamin C sufficiency has been linked with innate and adaptive immune response 
to infective agents (Sorice et al., 2014). In this regard, preclinical studies have shown that high dose 
vitamin C does exert anticancer effects in immunocompetent mice, where it can delay tumor growth 
in a T cell dependent fashion, both through enhanced cytotoxicity of adoptively transferred T cells 
and cooperatively with immune checkpoint therapeutics (Magri et al., 2020). While a number of high 
dose vitamin C clinical trials have been completed (Table 2), to date the results have not been 
encouraging. Perhaps design of future trials will benefit from the immunological approach, but for 
this tactic to reach general acceptance, a number of remaining questions need to be addressed (e.g. 
(Carr and Cook, 2018)). 
It can be argued that all types of cytotoxic cancer drugs cause direct, or indirect, oxidative stress. 
Nevertheless, a number of drugs have been developed using redox platforms to target various 
pathways. There are assorted categories that define their mechanisms of action: i) Adjuvants that 
protect normal tissues when given in combination with standard cancer drugs (amifostine, MESNA, 
NOV-002); ii) Drugs that interfere directly with GSH homeostasis (BSO); iii) Those that act as soft 
electrophiles in a chemoprevention setting by stimulating expression of ARE-regulated gene 
expression (sulforaphane); iv) Hard electrophiles that covalently modify thiol groups in target 
proteins (arsenic trioxide, Auranofin, PX-12, Telcyta); v) Modification of target thiols through Michael 
addition (ethacrynic acid, PRIMA-1, APR-246). While this collection of drugs has diverse 
characteristics, the common theme is the nucleophilicity of cysteine thiol groups, whether within 
specific drug targets, or in the context of general stress response. Perhaps because of the critical 
importance of redox homeostasis in both normal and tumor cells and aspects of functional 
redundancy, limited clinical success has been an essential characteristic of this group of redox 
targeted drugs, nevertheless efforts to discover and develop new agents continue. 
      In context, many cancer cell lines are relatively resistant to death by BSO-initiated GSH 
depletion. This may be because TXN-based antioxidant systems compensate for depletion of GSH 
(Harris et al., 2015), or because by upregulating HSF1 or increasing expression of deubiquitinases, 
tumor cells acquire tolerance of the effects of oxidative stress by attenuating their sensitivity to 
proteotoxicity and ER stress caused by protein misfolding (Harris et al., 2019). Together, these 
findings suggest that tumors can frequently circumvent redox targeting and that combinatorial 
approaches may be more successful. In fact, a number of combinatorial clinical trials are emerging 
with new redox active agents.  For example, erastin is a small molecule modulator of voltage 
dependent anion channels (VDAC2/VDAC3, (Yagoda et al., 2007)) and of the GSH transporter xCT 
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(Dixon et al., 2012). Treatment of cells with erastin causes GSH depletion, leading to inhibition of 
GPX4, which, in turn, increases ROS exposure (presumably through Fenton chemistry), triggering 
ferroptosis (Yang et al., 2014). Although erastin does not possess optimal therapeutic drug-like 
properties, analogues are under development with a view to clinical testing (Larraufie et al., 2015). 
Perhaps unexpectedly, GLS1 has also been shown to be a viable redox drug target for a new small 
molecule, CB839.  NRF2 activation facilitates its antitumor effects, since in KEAP1 mutant lung 
cancer cells, GLS1 inhibition by CB839 reduces glutamine, thereby diminishing glutamate, which in 
turn limits cysteine and GSH levels (Sayin et al., 2017). Presently, lung cancers are a primary focus 
for clinical trials for CB839, but the effectiveness of GLS1 inhibition appears to be both tumor-type 
and oncogene signaling dependent (Romero et al., 2017). Also, indirectly impacting redox 
homeostasis and inducing cell death through ROS, a new IDH1 inhibitor, Ivosidenib (AG-120), was 
shown to selectively target different mutants of IDH1 without apparent off-target effects on other 
dehydrogenases. Multiple clinical trials in IDH1 mutant cancers are underway using this inhibitor in 
combination with other anticancer drugs (Popovici-Muller et al., 2018).  
There are examples where drugs can indirectly target redox pathways and homeostasis. For 
example, when solid cancers disseminate, metastases frequently have phenotypic characteristics 
that are distinct from the parent tumor cells. In melanomas, circulating cells that go on to form distant 
metastatic lesions have reversible adaptive changes that select for survival in a more biologically 
oxidative environment. Such adaptations include increased dependence on NADPH generating 
enzymes in the folate pathway (Piskounova et al., 2015) and increased expression of the 
monocarboxylate transporter, MCT1 (Tasdogan et al., 2020). Since chemotherapy is one of the few 
approaches available for the treatment of metastases, interference with one carbon metabolism with 
drugs such as methotrexate or impeding lactate/pyruvate metabolism and transport have potential 
as indirect means to interfere with redox regulation and restrict metastasis. Sulfasalazine and erastin 
are unrelated chemical structures that have promiscuous binding affinities for a number of 
intracellular targets. However, they do share the ability to inhibit the xCT glutamate cystine antiporter 
and when used in combinations, have the potential to enhance the cytotoxic effects of other 
anticancer agents (Gout et al., 2001; Sayin et al., 2017). Moreover, combined inhibition of GSH 
(sulfasalazine) and TXN/TXNRD (Auranofin) pathways has been found to lead to synergistic cancer 
cell death implying roles for these complementary antioxidants in therapeutic intervention (Harris et 
al., 2015).     
Radiation therapies cause release of ROS at levels contingent upon dose and time. There is a 
vast literature on stress responses consequent to radiation and general consensus that the nexus 
of TP53/APE1/NRF2 transcription factors contribute to a regulated response. Moreover, implicit in 
assessing tumor and normal tissue responses is the concept of dose versus time thresholds that 
determine the extent of response (Murray et al., 2018). As a translational biomarker, it has been 
possible to titrate the ROS caused by radiation exposure by measuring the occurrence of S-
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glutathionylated serine protease inhibitor (Serpin) in the blood of prostate cancer patients (Zhang et 
al., 2019). Interestingly, in a phase I clinical trial, pharmacological administration of vitamin C 
intravenously, in combination with gemcitabine and radiotherapy, has been found to be well tolerated 
and effective, suggesting redox biology could be used to selectively target tumor tissue whilst 
protecting normal tissue (Alexander et al., 2018). 
 
8. Concluding comments 
Throughout tumorigenesis, cancer cells have to endure oxidative stress at initiation, upon matrix 
detachment, during passage in the circulation, and when disease recurs following therapy. These 
episodes can be mitigated by tumor cells through various adaptive strategies, each of which ensures 
ROS levels are restricted to a dynamic range that allows proliferation whilst avoiding cell death. 
During initiation, preneoplastic cells typically experience a high and sustained oncogene-generated 
ROS burden and they are therefore obliged to upregulate their antioxidant defences, which often 
entails overexpression of NRF2-regulated antioxidant genes, but can also involve oncogene-directed 
phosphorylation of PKM2 that increases NADPH production by diverting glucose metabolism down 
the PPP. During cancer progression, cooperation between neoplastic cells and CAFs and TAMs in 
their microenvironment results in ROS-stimulated migration and anchorage-independent growth of 
tumor cells, requiring them to reconfigure metabolism to increase NADPH generation via the actions 
of G6PD and/or IDH. During metastasis, circulating tumor cells experience high ROS levels following 
intravasation and existence in the blood, again requiring them to increase NADPH production, but in 
this case through increased use of the folate pathway (one-carbon metabolism) and upregulation of 
ALDH1L2, and to a lesser extent MTHFD1, whilst also ensuring glycolysis is maintained. In instances 
of post-therapy dormancy/recurrence, tumor cells depend on NRF2-directed gene expression to 
survive the switch to β-oxidation of fatty acids, rather than glycolysis, for energy. 
Although overexpression of antioxidant genes, increased GSH synthesis, and increased NADPH 
generation will prevent oxidative stress, it is not certain that the ‘roll out’ of the different tiers of 
oxidative stress defences during tumorigenesis and recurrence is orchestrated in precisely the order 
proposed above, and thus clarifying the stage-specific strategies employed by tumor cells warrants 
further study. It may be more plastic than implied, and depend largely on the severity of the ROS 
burden preneoplastic cells have to counter at initiation of tumorigenesis, and also on the subcellular 
compartments where oxidative stress arises. For example, a high ROS burden at initiation may 
necessitate stochastic genetic changes including somatic mutations in NFE2L2 or KEAP1 that are 
irreversible, whereas a lower ROS burden might be accommodated by reversible activation of 
members of the antioxidant transcription factor network and NADPH-generating pathways. It seems 
likely the adaptive mechanisms adopted at initiation will affect profoundly how tumor cells 
subsequently behave during cancer progression and to stimuli that dictate EMT and MET. It is 
striking that, as described above, adaptation to oxidative stress during cancer progression and 
 29 
metastasis entails bolstering NADPH-dependent antioxidant defences within the mitochondrion, 
which might not be so important during initiation and promotion of tumorigenesis. These 
observations suggest that mitochondrial function in cancer cells, and the dysregulation of particular 
mitochondrial metabolic pathways, may play a pivotal role in dictating which adaptive mechanisms 
are ‘available’ in the later stages of tumorigenesis. It is also unclear the extent to which constitutive 
activation of NRF2 at initiation influences either the ability of tumor cells to adapt to oxidative stress 
during, and after therapy, or the necessity of tumor cells to adapt to oxidative stress during, and after 
therapy, and thus increases the likelihood of recurrent disease. 
As we are only beginning to appreciate that redox homeostasis is of critical importance in cancer, 
there remain issues that need to be addressed. It is for example unclear how the antioxidant 
transcription factor network operates during different stages of tumorigenesis. In particular, the: i) 
ROS thresholds that activate individual members of the network; ii) extent to which thresholds for 
individual transcription factors change during the course of tumorigenesis, and upon constitutive 
activation of NRF2 or AP-1, or loss of TP53 function; iii) degree of cross-talk between the factors 
during tumorigenesis; iv) impact of other forms of stress, such as metabolic stress, hypoxia and 
inflammation, on the thresholds. An area that warrants further work is one that will determine the 
extent to which oxidative stress drives EMT, and the contribution of mitochondrial ROS to this 
process. Clarifying redox thresholds that influence EMT and MET will likely illuminate key 
biochemical pathways that influence the ability of different types of tumor cell to metastasise. It will 
also be important to provide a better understanding of factors controlling the acetylation of SOD2, 
and thus cause SOD2 to adopt prooxidant rather than antioxidant properties, during tumorigenesis. 
Lastly, the effects of antioxidants on the progression and metastatic stages of tumorigenesis are 
perplexing. Hopefully research that provides a better understanding of how oscillations between 
EMT and TME are controlled will clarify the adaptive mechanisms employed by different types of 
tumor cell in order to colonise distant tissues. The effects of antioxidants on ERK signaling in different 
tumor types should be further investigated, as should the possibility that antioxidants stimulate 
reductive stress in certain tumor types. Addressing these areas will improve therapeutic strategies. 
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Chemical properties and sources of ROS and RNS 
Amongst different ROS [i.e. superoxide anion radical (O2–); hydrogen peroxide (H2O2); hydroxyl 
radical (HO)] and RNS [i.e. nitric oxide (NO); peroxynitrite anion (ONOO–)], each has distinct 
physicochemical properties and half-lives. Amongst these ROS, HO is the most oxidising, followed 
by O2–, with H2O2 as a relatively weak oxidant  (Buettner, 1993). Whilst H2O2 and NO are 
indispensable as signaling molecules, O2– and ONOO– are highly reactive and can damage 
intracellular macromolecules, including polyunsaturated fatty acids (PUFAs) and nucleic acids. 
Oxidation of PUFAs by ROS leads to lipid peroxidation, where peroxidised PUFAs, together with 
their breakdown products (e.g. 4-hydroxy-2-nonenal (4-HNE)), can act as signaling molecules to 
stimulate inflammation, apoptosis or ferroptosis (Breitzig et al., 2016; Dodson et al., 2019). 
Principal intracellular sources of ROS include: leaking of electrons to O2 in mitochondria by 
reverse electron transport at complex I, or reaction between a semiquinone form of CoQ with O2 at 
complex III of the respiratory chain (Murphy, 2009); reduction of O2 to O2– by NADPH oxidases 
(NOX1-5 and DUOX1/2) during growth factor signaling (Brown and Griendling, 2009); production of 
H2O2 during protein folding within the endoplasmic reticulum (ER) (Ye et al., 2017). 
Less significant sources of ROS arise from the activities of cytochrome P450 (CYP), monoamine 
oxidase, xanthine oxidase, cyclooxygenase (COX), glycolate oxidase, hydroxyacid oxidase, 
aldehyde oxidase and amino acid oxidase (Sies and Jones, 2020). Formation of the particularly 
reactive HO from H2O2 occurs through Fenton chemistry that typically involves transition metal ions 
of iron, copper or manganese. The principal RNS in the cell is the vasodilator NO, produced by 
nitric oxide synthase (NOS) from L-arginine, with the inducible NOS2 isoenzyme largely responsible 




To prevent unrestrained accumulation of ROS and RNS, cells contain a spectrum of antioxidants. 
Non-catalytic small-molecules that directly scavenge ROS and RNS include endogenously-
synthesised bilirubin, α-lipoic acid, melatonin, melanin, GSH and uric acid, as well as exogenously-
derived vitamin E, vitamin C, β-carotene and plant polyphenols (Halliwell and Gutteridge, 2015). 
Amongst these, GSH is noteworthy because its synthesis is subject to homeostatic regulation (see 
below) and is often increased in a variety of cancer types (Gamcsik et al., 2012). 
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Catalytic antioxidants that scavenge O2– include cytosolic copper/zinc superoxide dismutase 
(CuZnSOD, or SOD1), mitochondrial manganese MnSOD (SOD2), extracellular EC-SOD (SOD3), 
each of which catalyses the conversion of O2– to H2O2 and O2 (Sheng et al., 2014). SOD2 is of 
particular importance for viability as its knockout in mice results in perinatal death. Collectively, SOD 
isoenzymes can attenuate NOX-dependent redox signaling associated with activation of receptor 
tyrosine kinases and G-protein-coupled receptors, probably by facilitating production and 
maintenance of a diffusible H2O2 signal (Parascandolo and Laukkanen, 2019). Both SOD1 and 
SOD2 protect against spontaneous tumorigenesis, and whilst they have been referred to as tumor 
suppressors they may also be upregulated during tumorigenesis (Gill et al., 2016). 
Enzymes that scavenge H2O2 include catalase (CAT), which converts H2O2 to H2O and O2 
(Kirkman and Gaetani, 2007), as well as peroxiredoxins (PRDXs, also called PRXs) and glutathione 
peroxidases (GPXs) that reduce H2O2 to H2O (Brigelius-Flohe and Maiorino, 2013; Elko et al., 2019). 
In this context, the PRDXs are of particular physiological significance because they are abundant, 
have high catalytic activities, and reduce >90% of cellular peroxides; they are subdivided into 
‘Typical’ 2-Cys PRDX1-5, ‘Atypical’ 2-Cys PRDX5, and 1-Cys PRDX6. Importantly, reduction of H2O2 
by PRDX1-5 is at the expense of oxidising TXN (simplified to thioredoxin-(SH)2), which results in 
condensation of two SH groups, and yields thioredoxin-S2 with an intramolecular disulfide bridge 
(Perkins et al., 2015). By contrast, reduction of H2O2 by the 1-Cys PRDX6 requires GSH, rather than 
TXN (Fisher, 2017). Reduction of H2O2 by GPXs also requires GSH, but in this case it results in 
condensation between the Cys thiol (-SH) groups of two GSH molecules, yielding GSSG that 
contains an intermolecular disulfide bridge (Deponte, 2013). Besides limiting ROS levels, PRDXs 
and GPXs also counter the actions of RNS by contributing to the elimination of NO, the reduction 
of ONOO– and also protein denitrosylation (Benhar, 2018). 
In addition, sestrins (SESN1, 2 and 3) exert indirect antioxidant activity (Sanchez-Alvarez et al., 
2019), in part by activation of transcription factor nuclear factor-erythroid 2 p45-related factor 2 
(NRF2) and inhibition of mTORC1 (Rhee and Bae, 2015). 
 
Box 3 
a) Heme and iron-dependent proteins in antioxidant defences 
Heme oxygenase isoenzymes (HO-1/2, encoded by HMOX1/2) serve as indirect antioxidants 
because they prevent free heme released from hemoproteins during oxidative stress from forming 
free radicals, and also because they participate in formation of bilirubin (Gozzelino et al., 2010). 
Proteins that sequester transition metals, or transport them from the cell, are also indirect-acting 
antioxidants because they suppress formation of HO from H2O2 by Fenton chemistry: these include 
ferritin (comprising light FTL1 and heavy FTH1 subunits), ferroportin (FPN1/SLC40A1), 
metallothionein and ceruloplasmin (Arosio et al., 2009; Pietrangelo, 2017). The ability of FTL1, FTH1 
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and FPN1 to limit intracellular levels of free intracellular iron helps prevent the redox cycling of 
Fe2+/Fe3+ that leads to lipid peroxidation and the likelihood of ferroptosis (Manz et al., 2016). 
b) Drug-metabolising enzymes in antioxidant defences 
As certain xenobiotics are pro-oxidant, drug-metabolising enzymes are often regarded as indirect-
acting antioxidants. These include the phase I aldehyde dehydrogenase (ALDH) family, the aldo-
keto reductase (AKR) family, carbonyl reductases (CBR), NAD(P)H:quinone oxidoreductase 
isoenzymes (NQO1 and 2) and short-chain dehydrogenases/reductases, as well as the phase II 
glutathione S-transferase (GST) family and the UDP-glucuronosyl transferase (UGT) family. Their 
actions prevent quinones and hydroquinones from redox-cycling, and electrophiles and lipid 
peroxidation products from depleting GSH (Hayes et al., 2005; Jin and Penning, 2007; Oppermann, 
2007; Rodriguez-Zavala et al., 2019; Rowland et al., 2013). Moreover, drug-metabolising enzymes, 
along with GPX4, inactivate 4-HNE and other lipid-derived signaling molecules that can trigger 
apoptosis and ferroptosis (Breitzig et al., 2016; Dodson et al., 2019). 
c) Sirtuin 3 as an indirect antioxidant 
Sirtuin 3 (SIRT3) is a NAD+-dependent deacetylase involved in many aspects of mitochondrial quality 
control (Gomes et al., 2020; Meng et al., 2019). By catalysing the deacetylation of SOD2, SIRT3 
increases scavenging of O2– in mitochondria, and by catalysing the deacetylation of IDH2, SIRT3 
increases generation of NADPH in mitochondria (Kincaid and Bossy-Wetzel, 2013). Furthermore, 
SIRT3 exerts multiple effects on mitochondrial metabolism by deacetylating acetyl-CoA synthase 2, 
long-chain acyl-CoA dehydrogenase and liver kinase B1 (Gomes et al., 2020). 
 
Box 4 
a) Glutathione synthesis and salvage 
GSH homeostasis is achieved through de novo synthesis and salvage pathways. An ancillary tier of 
indirect-acting antioxidant proteins exists that supplies glutamate, cysteine and glycine as building 
blocks for GSH synthesis. These include glutamine transporters, GLS1 and GLS2, the cystine-
glutamate SLC7A11/xCT antiporter and the glycine transporter SLC6A9, as well as components of 
serine-glycine one-carbon metabolism that produce cysteine from serine and glycine (Ducker and 
Rabinowitz, 2017; Koppula et al., 2018). Also in this category, are the GSH biosynthetic enzymes 
glutamate-cysteine ligase (GCL, previously called γ-glutamylcysteine synthetase (γGCS), 
comprising catalytic (GCLC, or γGCSh) and modifier (GCLM, or γGCSl) subunits), and glutathione 
synthetase (GSS), in which GCL catalyses the initial rate-limiting step and GSS the second and final 
step (Lu, 2013). In cancer cells, expression of GCLC and GCLM are important determinants of 
sensitivity to both chemo- and radio-resistance (Lin et al., 2018; Liu et al., 2017), and high levels can 
be associated with poor prognosis following surgery (Sun et al., 2019). The γ-glutamyl cycle is 
responsible for the primary de novo synthesis of GSH, with the rate-limiting enzyme being GCL. 
Recycling of glutamate, cysteine and glycine salvages GSH, a process accomplished by various 
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enzymes including the membrane-associated hydrolase GGT that acts on GSH, GSSG and GS-
adducts. CHAC1 and CHAC2 as broad specificity γ-glutamyl cyclotransferases can degrade GSH: 
CHAC1 converts GSH to 5-oxoproline and cysteinylglycine (Oakley et al., 2008), and its expression 
may be dysregulated in breast and ovarian cancer (Goebel et al., 2012). 
b) Thioredoxins in redox homeostasis 
The ‘cytosolic’ TXN1 and mitochondrial TXN2 are both small reductases that catalyse cysteine thiol-
disulfide exchange reactions via a Cys-Gly-Pro-Cys motif in their active-sites (Lu and Holmgren, 
2014). The antioxidant function of TXNs is demonstrated principally through their abilities to transfer 
electrons to oxidised PRDX1-5, methionine sulfoxide reductases and redox-sensitive transcription 
factors, thereby allowing their substrates to be reduced back to a more active state. This process 
results in oxidation of Cys residues in the active-sites of TXN1 or TXN2, which can in turn be reduced 
by the selenoproteins TXNRD1 or TXNRD2, respectively, using NADPH as a cofactor. Thus TXN1/2-
mediated reduction of PRDXs, methionine sulfoxide reductases and transcription factors is at the 
expense of NADPH and results in accumulation of NADP+. Similar to other redox pathways, the TXN 
antioxidant system is upregulated in a wide range of cancers (Jia et al., 2019) and is associated with 
poor prognosis (Leone et al., 2017). Overlap exists between the TXN system and GSH insofar as 
oxidised TXN1 can be reduced by glutaredoxins (GRX1 and 2), using GSH as a cofactor, and so 
under certain circumstances can replace TXNRD1 (Deponte, 2013; Ren et al., 2017). Furthermore, 
GSSG can be reduced by the TXN system, creating redundancy between the TXN- and GSH-based 
antioxidant systems. In tumors with compromised GSH homeostasis, inhibition of TXN/TXNRD 
induces synthetic lethality (Yan et al., 2019). 
 
Box 5 
NADPH-based redox couples are central to antioxidant defences 
NADPH is a fundamentally important metabolite in the reductive biosynthesis of macromolecules, 
and is indispensable for cellular antioxidant defences. By binding to CAT, NADPH prevents 
inactivation of the enzyme by H2O2 and maintains its antioxidant capacity (Kirkman and Gaetani, 
2007). Importantly, NADPH provides reducing equivalents that allow GSH to be generated from 
GSSG and thioredoxin-(SH)2 to be generated from thioredoxin-S2 by the catalytic actions of 
glutathione reductase (GSR) and thioredoxin reductases (TXNRD1 and TXNRD2), respectively 
(Ying, 2008). In turn, GSH and TXN enable GPXs and PRDXs to fulfil their antioxidant roles. To 
support proliferation, NADPH synthesis is frequently elevated in tumor cells (Purohit et al., 2019). 
As NADPH exists as a redox couple with NADP+, and is constantly oxidised in aerobic conditions, 
it has to be continuously regenerated. This is primarily achieved by enzymes in the oxidative arm of 
the pentose phosphate pathway (PPP), glucose-6-phosphate dehydrogenase (G6PD) and 6-
phosphogluconate dehydrogenase (6PGD) that provide ribose-5-phosphate, malic enzymes (ME1, 
2 and 3) that provide pyruvate for the TCA cycle, and the serine-driven one-carbon metabolism 
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enzymes methylenetetrahydrofolate dehydrogenase (MTHFD2), which forms the purine precursor 
10-formyl-tetrahydrofolate, and aldehyde dehydrogenase 1L2 (ALDH1L2) that releases CO2 from 
10-formyl-tetrahydrofolate (Ciccarese and Ciminale, 2017). Amongst these enzymes, ME1 has been 
reported to physically interact with, and activate, both 6PGD and G6PD, suggesting a level of 
coordinated regulation of these NADPH-generating enzymes that may be relevant in cancer cells 
(Yao et al., 2017). Under hypoxic conditions, the production of NADPH by MTHFD2 in MYC-
transformed tumor cells can be enhanced by inducing serine hydroxymethyltransferase (SHMT2), 
which encodes an enzyme that catalyzes transfer of CH3 from serine to tetrahydrofolate and so 
increases substrate availability for MTHFD2 (Ye et al., 2014). 
Other enzymes that generate NADPH include isocitrate dehydrogenase (IDH1/2), nicotinamide 
nucleotide transhydrogenase (NNT) and glutamate dehydrogenase (GDH1/2). The NADP+-
dependent IDH1 and IDH2 catalyse reversible oxidative decarboxylation of isocitrate to yield α-
ketoglutarate (α-KG) and CO2, whereas NNT transfers reducing equivalents from NADH to NADPH 
using the electron transport chain proton gradient (Purohit et al., 2019). Under hypoxic conditions, 
cancer cells can employ IDH2 to reductively carboxylate α-KG obtained anaplerotically from 
glutamine and produce citrate at the expense of NADPH, which is compensated for by increased 
oxidation of α-KG to succinyl-CoA that provides NADH, and is in turn used by NNT to produce 
NADPH (Mullen et al., 2014). GDH1 and GDH2 catalyse the reversible oxidative deamination of 
glutamate to α-KG using NAD(P)+ as cofactor (Plaitakis et al., 2017), but do not seem to contribute 
substantially to redox homeostasis (Fan et al., 2014b). 
Somatic mutations in IDH1 and IDH2 have been reported in a range of solid and hematological 
malignancies arising early during tumorigenesis and consistent with events representing driver 
mutations; the mutations are heterozygous and neomorphic as they result in production of the 
oncometabolite 2-hydroxyglutarate (Dang and Su, 2017). In this instance, IDH1/2 encoded by the 
mutant gene acquires the ability to catalyse NADPH-dependent conversion of α-KG to 2-
hydroxyglutarate as a consequence of substitutions that increases its affinity for NADPH and α-KG 
and cause loss of oxidative decarboxylation activity (Golub et al., 2019). The 2-hydroxyglutarate 
produced by mutant IDH1/2 inhibits competitively many 2-oxoglutarate−dependent dioxygenases, 
such as histone demethylases and DNA hydroxylases, and it is well established that this perturbs 
epigenetic mechanisms and thus cell differentiation. In addition, 2-hydroxyglutarate inhibits branched 
chain amino acid transaminases BCAT1 and BCAT2 that catalyse interconversion of 2-oxoglutarate 
with glutamate, resulting in a reduction in intracellular levels of glutamate and GSH in cells 
harbouring mutant IDH1 that renders them sensitive to oxidative stress when treated with an inhibitor 
of glutaminase (GLS1 and GLS2) (McBrayer et al., 2018). As discussed later, inhibition of IDH 




Protein cysteines provide redox switches 
Cellular responses to ROS predicate on regulatory proteins containing thiol-based redox switches 
that when oxidised cause the protein to adopt new or distinct functions (Holmstrom and Finkel, 2014). 
Critical to the reactivity of individual cysteines within redox switches, is the apparent pK (pKa) of their 
thiol moieties. Proteins which are susceptible to oxidative modification contain cysteines with low 
pKa values that exist in the thiolate anion state at physiological pH, caused by the presence of 
adjacent basic amino acids. The various oxidation states of the thiol (SH)-containing side chain of 
cysteine within proteins creates a circumstance where quantitative changes in intracellular ROS can 
regulate protein activity. The thiol of cysteine as a thiolate anion (-S–) or cysteinyl radical (-S) is 
critical to its oxygen reactivity. Contingent upon the extent of oxidation, sulfenate (-SOH), sulfinate 
(-SO2H), sulfonate (-SO3H) or disulfide (-S−S-) species may be formed, with oxidation to sulfonate 
being essentially irreversible and requiring degradation of the protein to eliminate the modification. 
Also, S-glutathionylation (-SSG) and S-nitrosylation (-SNO) may result from exposure to ROS/RNS 
and sulfhydration/persulfidation (-SSH) from reaction with endogenous H2S (Yang et al., 2016a). 
S-glutathionylation may protect proteins from over-oxidation, or may alter their structure and 
function; thus, parallel to the kinase/phosphatase cycle is the S-glutathionylation cycle (Grek et al., 
2013). The forward protein S-glutathionylation reaction can be driven by GST Pi 1-1 (GST P1-1), 
which demonstrates several mechanisms of pleiotropy (Paaby and Rockman, 2013). In particular, 
GST P1-1 engages in promiscuous interactions with target proteins, identifying them as substrates 
for S-glutathionylation. GST P1-1 has catalytic cysteines near the surface of the substrate channel 
that can act as GS– donors. By contrast, in GST Omega 1-1 (GST O1-1), which catalyses 
deglutathionylation, the catalytic cysteine of each subunit is buried within the substrate channel, 
behaving as a GS– acceptor (Menon and Board, 2013). Deglutathionylation is also accomplished by 
GRX (Stroher and Millar, 2012) or SRXN1 (Findlay et al., 2006; Park et al., 2009). 
      With the exception of the sulfonate state, oxidised cysteines can be reduced, thereby recovering 
the protein’s homeostatic function. Oxidation of protein-S– to protein-SOH can be reduced by TXN 
and TXNRD, with NADPH as hydride donor. Similarly, protein-SSG and protein disulfide bridges 
formed from protein-SOH can be reduced by the actions of TXN, TXNRD, GSH, GSR, GST O1-1, 
GRX and NADPH. At higher ROS levels, protein-SOH may be further oxidised to protein-SO2H, 
some of which can be reduced to protein-SOH by SRXN1 (Akter et al., 2018). 
 
Box 7 
Functioning of the redox switch in PRDX, and associated “floodgate” hypothesis 
Antioxidant PRDX enzymes are a classic example of proteins regulated by redox. Each possesses 
a high-affinity H2O2-binding site, comprising a cysteine with a low pKa value that is readily oxidised, 
and therefore called a peroxidatic cysteine, or Cp (Perkins et al., 2015). In PRDX1-5, oxidation of 
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their CP residues by H2O2 to a sulfenic acid derivative results in formation of an intermolecular 
disulfide between the CP residue and another cysteine, the resolving Cys, or CR, present in the other 
subunit within the PRDX dimer. In turn, the CP−CR disulfide is reduced by the TXN1/2-TXNRD1/2-
NADPH system, thereby allowing regeneration of CP for reaction with H2O2, and completion of the 
catalytic cycle. For 1-Cys PRDX6, a monomeric enzyme with phospholipase activity that can reduce 
phospholipid hydroperoxides, its oxidised CP residue can be reduced by GSH, in a GST P1-
1−catalysed reaction (Fisher, 2017).  
As a consequence of their CP residues being oxidised to sulfinic acid, PRDXs can be inactivated 
under conditions where H2O2 levels are relatively high. This allows H2O2 to accumulate and fulfil 
signaling functions, where PRDXs are posited to act through peroxide floodgates (Wood et al., 2003). 
Inactivation of PRDXs can also occur through phosphorylation, providing a classic example of cross-
talk between kinase and redox signaling (Rhee et al., 2012).  Because of their abundance, sensitivity 
to oxidation and ability to physically interact with other proteins, PRDXs have been proposed to 




Figure and Table legends 
  
Figure 1. Metabolic responses to acute oxidative stress. In cells under normal redox homeostatic 
conditions (A), glucose is principally oxidised by glycolysis to pyruvate, and via acetyl-CoA through 
the tricarboxylic acid cycle, with G6PD inhibited by NADPH and minimal flux through the PPP. 
However, upon acute oxidative stress (B), feedback inhibition of G6PD by NADPH is greatly 
diminished (1) and Cys residues in GAPDH (2), ATM (3) and complexes I, III and IV of the electron 
transport chain (4) are oxidised, a combination of circumstances that result in inhibition of glycolysis, 
phosphorylation of G6PD and increased metabolism through the PPP. Moreover, oxidation of Cys 
residues in PTEN (5) causes activation of PKB/Akt, resulting in increased cell survival. 
 
Figure 2. NRF2 provides and inducible floodgate defence against oxidative stress. Under non-
stressed basal conditions (A), cellular redox homeostasis is maintained by constitutive expression 
of a battery of antioxidant genes. However, when exposed to acute oxidative stress (B), cells adapt 
to the increase in ROS levels by inducing genes encoding detoxification, GSH- and TXN-dependent 
antioxidants and NADPH-generating enzymes that are regulated by NRF2. Should the capacity of 
the antioxidant systems that are induced by NRF2 become saturated and therefore insufficient to 
counter additional oxidative stress (C), or prolonged oxidative stress causes activation of KLF9 and 
downregulation of NRF2, the excess levels of ROS that are not countered by the NRF2-directed 
defences then trigger additional redox switches that activate other members of the antioxidant 
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transcription factor network. When NRF2-orchestrated defences become saturated, activation of 
other members of the antioxidant transcription factor network may occur simultaneously, or they may 
be activated in a stratified manner with each transcription factor being activated at a distinct ROS 
threshold, which results in various cellular responses including metabolic reprogramming, damage 
repair, cell cycle arrest, senescence and apoptosis. 
 
Figure 3. Redox regulation of PTP- and PTEN-mediated inhibition of cell proliferation and survival. 
Protein tyrosine phosphatases PTP1B, PTPN2 and PTPN11 and the lipid phosphatase PTEN 
suppress MAPK and PKB/Akt activity, as well as NF-κB signaling (bottom left). These phosphatases 
each possess an active-site Cys residue in a thiolate anion (S–) state that is susceptible to oxidation: 
as depicted across the centre of the cartoon, the thiolate form of the active-site Cys can be oxidised 
to sulfenate (SOH), sulfinate (SO2H) or sulfonate (SO3H) states depending on the levels of H2O2 and 
duration of exposure to H2O2 (see Box 6). Alternatively, as shown at the top of the cartoon, the 
active-site Cys may form mixed disulfides by reacting with GSH (S-glutathionylated protein-SSG), 
that can be catalysed by GST P1-1, or react with another thiol internally or in another protein to form 
a disulfide bridge (-S−S-). These oxidative modifications of the phosphatases result in their 
inactivation and therefore an increase in MAPK and PKB/Akt activity and NF-κB signaling. However, 
oxidative inactivation to sulfenate or sulfinate states can be reversed by the TXN1 or SRXN1 
antioxidant systems (shown in green boxes), thereby allowing rescue of phosphatase activity and 
suppression of MAPK, PKB/Akt and NF-κB activities. Similarly, active-site Cys that have been S-
glutathionylated or have formed a disulfide bridge can be reversed by the GRX/GSH antioxidant 
system (green box), or de-glutathionylated by GST O1-1, thereby allowing recovery of phosphatase 
activity. Oxidation of the active site Cys to a sulfonate state is irreversible (right), and the protein has 
to be eliminated. 
 
Figure 4. An ambiguous role for oxidative stress in tumorigenesis. The cartoon depicts development 
of malignant disease from initiation through promotion and progression, until it acquires a highly 
malignant, invasive and metastatic phenotype. The contributions that excess levels of O2–, H2O2, 
HO and ONOO– may make to the different stages of the disease are indicated in panel at the 
bottom.  
 
Figure 5. Influence of oxidative stress on cell fate during early stages of tumorigenesis. The cartoons 
depict how levels of ROS stimulate proliferation or apoptosis in preneoplastic cells during initiation 
of tumorigenesis, and how ROS support EMT during progression of tumorigenesis by altering TGF-
β signaling and by activation of antioxidant transcription factors that control expression of EMT-TFs. 
During the earliest stages of tumorigenesis (A), activation of oncogenes, coupled with higher 
metabolic demands, results in an increase in intracellular ROS levels in early neoplastic 
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lesions/adenomas. In order to benefit from the proliferative advantages associated with the increase 
in ROS, without succumbing to apoptosis, cells harbouring activated oncogenes augment their 
antioxidant capacity by increasing transactivation of genes encoding GSH- and TXN-dependent 
enzymes along with antioxidant/detoxification enzymes (1). Often this readjustment of redox entails 
loss or blunting of repression of NRF2 by KEAP1 and induction of NRF2-target genes. In addition, 
HIF-1α increases expression of key metabolic proteins such as GLUT1, HK2 and MCT4. Also, NF-
κB and TP53 probably contribute to this adaptive process, though in lesions harbouring mutant TP53 
the latter is unlikely. Treatment of animals with BSO, which inhibits synthesis of GSH, prior to 
initiation of carcinogenesis will stimulate apoptosis of premalignant cells (2). However, once 
carcinogenesis has been initiated, stimulation of apoptosis in malignant cells requires inhibition of 
both the GSH- (by BSO) and the TXN- (by Sulfasalazine or Auranofin) based antioxidant systems. 
During the progression stage of tumorigenesis (B), EMT is triggered by a variety of environmental 
factors including those that alter intracellular redox. In this regard, TGF-β signaling (1), growth factor 
signaling (2) and tumor-associated macrophages (TAMs) in the microenvironment (3) will produce 
ROS. Binding of TGF-β to its cognate receptor causes phosphorylation of SMAD2/3 (4), induction of 
NOX4 gene expression (5), which results in production of H2O2 at the endoplasmic reticulum (6). 
NOX4-generated ROS within the tumor cell is augmented by growth factor signaling causing 
phosphorylation and activation of NOX1 and production of O2– at the plasma membrane (7), with 
elevated ROS increasing processing of latent TGF-β (8). The increases in ROS from TGF-β and 
growth factor signaling, along with those generated by TAMs, activate TP53, which combines with 
SMAD proteins to induce transcription of genes encoding the EMT-TFs SNAIL and TWIST (9). 
Similarly, increased ROS levels activate AP-1 (10) and HIF-1α (11) and induce SNAIL and TWIST, 
whereas the activation by ROS of NF-κB (12) leads to induction of genes encoding SNAIL, TWIST, 
SLUG, ZEB1 and ZEB2. Together, SNAIL, TWIST, SLUG, ZEB1 and ZEB2 positively control 
expression of mesenchymal-associated genes and negatively control expression of epithelial-
associated genes. ROS also activate HSF1 (13), whereas its downregulation decreases TGF-β-




Figure 6. Reductive glutamine metabolism and serine-driven folate metabolism suppresses 
mitochondrial ROS accumulation to support anchorage-independent growth and/or metastatic 
disease. (A) The increase in mitochondrial ROS that occurs when tumor cells are grown as 
spheroids can be mitigated by the concerted actions of IDH1 (1) and IDH2 (2), located in the 
cytoplasm and mitochondrion, respectively. Specifically, within the cytoplasm, IDH1 catalyses the 
reductive carboxylation of α-ketoglutarate (α-KG), obtained from glutamine (by the sequential 
actions of GLS1 and GDH, see top right of cartoon), utilising NADPH provided by the pentose 
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phosphate pathway (PPP, see top left and center of cartoon), to provide a supply of isocitrate and 
citrate. In turn, citrate in the cytoplasm is transferred to the mitochondrion via the citrate transporter 
protein (CPT, SLC25A1), before it is utilized by IDH2 to produce α-KG and NADPH. The latter is 
required to reduce GSSG and maintain high GSH levels, which ensures mitochondrial ROS levels 
are restrained and anoikis averted. Thus, IDH1 and IDH2 activities in the different sub-cellular 
compartments enable NADPH generated by the PPP, along with high glutamate/glutamine levels, 
to drive reductive carboxylation of α-KG in the cytoplasm, and so transfer reducing equivalents 
from the cytoplasm to the mitochondrion. (B) The 10-formyl-tetrahydrofolate (THF) pathway 
represents a major source of NADPH for a variety of cell lines grown under in vitro cell culture 
conditions.  For melanoma tumor cells to survive the relatively high O2 levels in the bloodstream 
and then colonise the liver, they increase production of NADPH by augmenting ALDH1L2 protein 
levels and maintaining levels of MTHFD1; ALDH1L2 (1) and MTHFD1 (2) are located in the 
mitochondrion and cytoplasm, respectively. The cartoon depicts how high de novo synthesis of 
serine, derived from glucose and 3-phosphoglycerate (top left-hand side), followed by transport 
into the mitochondrion, allows donation of a methyl group to THF, yielding 5,10-methylene-THF 
through a serine hydroxymethyl transferase (SHMT) 2-catalysed reaction. In turn, 5,10-methylene-
THF within the mitochondrion is converted to 10-formyl-THF by MTHFD2, which can in turn be 
utilised by ALDH1L2 to form NADPH (bottom right-hand side) that maintains GSH levels and 
prevents excess ROS from accumulating. Alternatively, 10-formyl-THF can be used by MTHFD1L 
to generate formate, which when transported out of the mitochondrion can be used in reversible 









Table 1. Redox homeostasis-associated genes regulated by members of the antioxidant 









Table 2. Overview of drugs that target redox platforms. 
Drug Mechanism of action Notes Reference 
Amifostine Aminothiol used to protect 
normal tissues against 
radiation toxicities. 
FDA approved in esophageal cancer. (Shen et al., 2001) 
MESNA Thiol used with alkylating 
agents to protect bladder. 




NOV-002 Mimetic of GSSG. Designed 
to interfere with cancer 
cell GSH homeostasis 
while protecting bone 
marrow. 
Negative results in Phase 3 clinical 
trials. 




Inhibitor of de novo GSH 
biosynthesis. 
Phase 1/2 clinical trials showed dose-
limiting liver toxicity. 
(O'Dwyer et al., 
1992) 




Tested in a variety of preclinincal and 
clinical settings. 
(Hail et al., 2008) 
Arsenic trioxide Cross-links vicinal thiols in 
sensitive proteins.  
FDA approved promyelocytic leukemia. (Wang and Chen, 
2008) 
Auranofin Non-specific binding, but 
inhibits thioredoxin 
reductase. 
Plausible use in ovarian cancer. (Fan et al., 
2014a) 
PX-12 Irreversible inhibitor of 
thioredoxin-1. 
Following drug administration, patients 
experienced strong, dose-limiting 
sulfurous odors. 
(Baker et al., 
2006) 
Telcyta Alkylating prodrug activated 
by GSTP. 
Negative results Phase 3 clinical trials. (Tew, 2005) 
Telintra Small molecule inhibitor of 
GSTP. 
Clinical benefit in myelodysplastic 
syndrome patients. 
(Ruscoe et al., 
2001) 
Ethacrynic acid Michael addition chemistry 
reacts with thiols.  
FDA approved as a diuretic; used in 
combination with alkylating agents; 
dose-limiting fluid imbalance in cancer 
patients. 




Michael addition chemistry 
with apparent specificity 
towards p53 
Restores wild type functions of p53. 
Testing in progress. 
(Ogiwara et al., 
2019) 
Erastin Small molecule modulator of 
VDAC and inhibitor of 
Gpx4 
Analogue development leads to Phase 
1 study of PRLX 93936. 
(Yang et al., 
2014) 
Ascorbate High doses cause high H2O2 
& deplete GSH & NADPH 
Numerous Phase I/II trials but as yet, 
no consensus on efficacy.  
(Chen et al., 
2005) 
CB-839 Inhibits glutaminase 1 
(GLS1), limits glutamine, 
reduces glutamate & 
cysteine 
Evidence of cancer specificity based 
on salvage pathways. Ongoing Phase 
I/II trials in combinations. 




Inhibits mutant IDH1 variants 
with concomitant 
depletion of NADPH and 
GSH pools 
Numerous Phase I/II trials. Phase III 
with azacytidine in AML. 
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